WO2025252084A1 - Agents de dégradation bifonctionnels de pak4, compositions pharmaceutiques et applications thérapeutiques - Google Patents

Agents de dégradation bifonctionnels de pak4, compositions pharmaceutiques et applications thérapeutiques

Info

Publication number
WO2025252084A1
WO2025252084A1 PCT/CN2025/098860 CN2025098860W WO2025252084A1 WO 2025252084 A1 WO2025252084 A1 WO 2025252084A1 CN 2025098860 W CN2025098860 W CN 2025098860W WO 2025252084 A1 WO2025252084 A1 WO 2025252084A1
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
hydrogen
deuterium
alkyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2025/098860
Other languages
English (en)
Inventor
Jinshan Chen
Qiang Guo
Xilong XU
Jinquan Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Convergen Suzhou Pharmaceutical Co Ltd
Original Assignee
Convergen Suzhou Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergen Suzhou Pharmaceutical Co Ltd filed Critical Convergen Suzhou Pharmaceutical Co Ltd
Publication of WO2025252084A1 publication Critical patent/WO2025252084A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the present disclosure belongs to the pharmaceutical field and relates in particular to PAK4 protein degraders, pharmaceutical compositions thereof, and use thereof in treating, preventing, or ameliorating one or more symptoms of a PAK4-mediated disorder, disease, or condition.
  • PAK4 (p21-activated kinase 4) regulates a wide range of cellular functions and plays an important role in cancer cell motility, proliferation, and survival (Kumar et al., Gene 2017, 605, 20-31; Wang et al., Expert Opin. Ther. Pat. 2021, 31, 977-87) .
  • PAK4 is often upregulated in a variety of cancer, including breast cancer, esophageal cancer, gastric cancer, gliomas, hepatocellular carcinoma, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, and sarcomas (Kumar et al., Gene 2017, 605, 20-31; Rane and Minden, Sem. Cancer Biol.
  • PAK4 overexpression correlates with poor prognosis, tumor aggressiveness, and metastasis (Kumar et al., Gene 2017, 605, 20-31; Wang et al., Expert Opin. Ther. Pat. 2021, 31, 977-87) .
  • Small molecule PAK4 inhibitors have been shown to be effective in inhibiting tumor growth (Murray et al., Proc. Natl. Acad. Sci. USA 2010, 107, 9446-51; Rane et al., Sci. Rep. 2017, 7, 42555) . However, clinical studies of the first PAK4 inhibitor were terminated due to poor selectivity, cellular activity, or pharmacokinetic properties (Wang et al., Expert Opin. Ther. Pat. 2021, 31, 977-87) .
  • the present disclosure provides a compound of Formula (I) : or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof;wherein, is a single bond or a double bond;R 1 is (i) hydrogen, deuterium, or halo; (ii) C 1-6 alkyl, or C 1-6 haloalkyl; or (iii) 5-to 6-membered heteroaryl, which is optionally substituted with OH, or NH 2 ;R 2 is (i) hydrogen, deuterium, or halo; (ii) C 1-6 alkyl, or C 1-6 haloalkyl; or (iii) 5-to 6-membered heteroaryl, which is optionally substituted with OH,
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient.
  • the present disclosure provides use of a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in the manufacture of a medicament for treating or preventing a PAK4-mediated disorder, disease, or condition, or ameliorating one or more symptoms of a PAK4-mediated disorder, disease, or condition.
  • the present disclosure provides use of a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in the manufacture of a medicament for treating or preventing a proliferative disease, or ameliorating one or more symptoms of a proliferative disease.
  • the present disclosure provides use of a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in the manufacture of a medicament for inhibiting the growth of a cell.
  • the present disclosure provides use of a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in the manufacture of a medicament for inducing degradation of a PAK4.
  • the present disclosure provides a method of treating or preventing a PAK4-mediated disorder, disease, or condition, or ameliorating one or more symptoms of a PAK4-mediated disorder, disease, or condition in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • a compound of Formula (I) or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate,
  • the present disclosure provides a method of treating or preventing a proliferative disease, or ameliorating one or more symptoms of a proliferative disease in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • a compound of Formula (I) or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • the present disclosure provides a method of inhibiting the growth of a cell, comprising contacting the cell with an effective amount of a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • a compound of Formula (I) or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • the present disclosure provides a method of inducing degradation of a PAK4, comprising contacting the PAK4 with an effective amount of a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • a compound of Formula (I) or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • the present disclosure provides a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, for use in treating or preventing a PAK4-mediated disorder, disease, or condition, or ameliorating one or more symptoms of a PAK4-mediated disorder, disease, or condition.
  • the present disclosure provides a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, for use in treating or preventing a proliferative disease, or ameliorating one or more symptoms of a proliferative disease.
  • the present disclosure provides a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, for use in inhibiting the growth of a cell.
  • the present disclosure provides a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, for use in inducing degradation of a PAK4.
  • subject refers to an animal, including, but not limited to, a primate (e.g., human) , cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse.
  • primate e.g., human
  • subject and patient are used interchangeably herein in reference, for example, to a mammalian subject, such as a human subject. In one embodiment, the subject is a human.
  • treat, ” “treating, ” and “treatment” are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or alleviating or eradicating the cause (s) of the disorder, disease, or condition itself.
  • prevent, ” and “prevention” are meant to include a method of delaying and/or precluding the onset of a disorder, disease, or condition, and/or its attendant symptoms; barring a subject from acquiring a disorder, disease, or condition; or reducing a subject’s risk of acquiring a disorder, disease, or condition.
  • alleviate and “alleviating” refer to easing or reducing one or more symptoms (e.g., pain) of a disorder, disease, or condition.
  • the terms can also refer to reducing adverse effects associated with an active ingredient.
  • the beneficial effects that a subject derives from a prophylactic or therapeutic agent do not result in a cure of the disorder, disease, or condition.
  • contacting or “contact” is meant to refer to bringing together of a therapeutic agent and a biological molecule (e.g., a protein, enzyme, RNA, or DNA) , cell, or tissue such that a physiological and/or chemical effect takes place as a result of such contact. Contacting can take place in vitro, ex vivo, or in vivo.
  • a therapeutic agent is contacted with a biological molecule in vitro to determine the effect of the therapeutic agent on the biological molecule.
  • a therapeutic agent is contacted with a cell in cell culture (in vitro) to determine the effect of the therapeutic agent on the cell.
  • the contacting of a therapeutic agent with a biological molecule, cell, or tissue includes the administration of a therapeutic agent to a subject having the biological molecule, cell, or tissue to be contacted.
  • terapéuticaally effective amount or “effective amount” is meant to include the amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disorder, disease, or condition being treated.
  • therapeutically effective amount or “effective amount” also refers to the amount of a compound that is sufficient to elicit a biological or medical response of a biological molecule (e.g., a protein, enzyme, RNA, or DNA) , cell, tissue, system, animal, or human, which is being sought by a researcher, veterinarian, medical doctor, or clinician.
  • a biological molecule e.g., a protein, enzyme, RNA, or DNA
  • pharmaceutically acceptable carrier refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material.
  • each component is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of a subject (e.g., a human) without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, and commensurate with a reasonable benefit/risk ratio.
  • the term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term “about” or “approximately” means within 1, 2, or 3 standard deviations. In certain embodiments, the term “about” or “approximately” means within 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05%of a given value or range.
  • alkyl refers to a linear or branched saturated monovalent hydrocarbon radical, wherein the alkyl is optionally substituted with one or more substituents Q as described herein.
  • C 1-6 alkyl refers to a linear saturated monovalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated monovalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the alkyl is a linear saturated monovalent hydrocarbon radical that has 1 to 30 (C 1-30 ) , 1 to 20 (C 1-20 ) , 1 to 15 (C 1-15 ) , 1 to 10 (C 1-10 ) , or 1 to 6 (C 1-6 ) carbon atoms, or branched saturated monovalent hydrocarbon radical of 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3-6 ) carbon atoms.
  • linear C 1-6 and branched C 3-6 alkyl groups are also referred as “lower alkyl.
  • alkyl groups include, but are not limited to, methyl, ethyl, propyl (including all isomeric forms, e.g., n-propyl and isopropyl) , butyl (including all isomeric forms, e.g., n-butyl, isobutyl, sec-butyl, and t-butyl) , pentyl (including all isomeric forms, e.g., n-pentyl, isopentyl, sec-pentyl, neopentyl, and tert-pentyl) , and hexyl (including all isomeric forms, e.g., n-hexyl, isohexyl, and sec-hexyl) .
  • alkylene and “alkanediyl” are used interchangeably herein in reference to a linear or branched saturated divalent hydrocarbon radical, wherein the alkylene or alkanediyl is optionally substituted with one or more substituents Q as described herein.
  • C 1-6 alkylene refers to a linear saturated divalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the alkylene is a linear saturated divalent hydrocarbon radical that has 1 to 30 (C 1-30 ) , 1 to 20 (C 1-20 ) , 1 to 15 (C 1-15 ) , 1 to 10 (C 1-10 ) , or 1 to 6 (C 1-6 ) carbon atoms, or branched saturated divalent hydrocarbon radical of 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3-6 ) carbon atoms.
  • linear C 1-6 and branched C 3-6 alkylene groups are also referred as “lower alkylene.
  • alkylene groups include, but are not limited to, methanediyl, ethanediyl (including all isomeric forms, e.g., ethane-1, 1-diyl and ethane-1, 2-diyl) , propanediyl (including all isomeric forms, e.g., propane-1, 1-diyl, propane-1, 2-diyl, and propane-1, 3-diyl) , butanediyl (including all isomeric forms, e.g., butane-1, 1-diyl, butane-1, 2-diyl, butane-1, 3-diyl, and butane-1, 4-diyl) , pentanediyl (including all isomeric forms, e.g., pentanediyl (including all isomeric forms, e.g., pentane-1, 1-diyl, pentane-1, 2-diyl, pen
  • substituted alkylene groups include, but are not limited to, –C (O) CH 2 –, –C (O) (CH 2 ) 2 –, –C (O) (CH 2 ) 3 –, –C (O) (CH 2 ) 4 –, –C (O) (CH 2 ) 5 –, –C (O) (CH 2 ) 6 –, –C (O) (CH 2 ) 7 –, –C (O) (CH 2 ) 8 –, –C (O) (CH 2 ) 9 –, –C (O) (CH 2 ) 10 –, –C (O) CH 2 C (O) –, –C (O) (CH 2 ) 2 C (O) –, –C (O) (CH 2 ) 3 C (O) –, –C (O) (CH 2 ) 4 C (O) –, or —C (O) (CH 2 ) 5 C (O) –.
  • heteroalkyl refers to a linear or branched saturated monovalent hydrocarbon radical that contains one or more heteroatoms on its main chain, each independently selected from O, S, and N.
  • the heteroalkyl is optionally substituted with one or more substituents Q as described herein.
  • C 1-6 heteroalkyl refers to a linear saturated monovalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated monovalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the heteroalkyl is a linear saturated monovalent hydrocarbon radical that has 1 to 30 (C 1-30 ) , 1 to 20 (C 1-20 ) , 1 to 15 (C 1-15 ) , 1 to 10 (C 1-10 ) , or 1 to 6 (C 1-6 ) carbon atoms, or branched saturated monovalent hydrocarbon radical of 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3-6 ) carbon atoms.
  • linear C 1-6 and branched C 3-6 heteroalkyl groups are also referred as “lower heteroalkyl.
  • heteroalkyl groups include, but are not limited to, –OCH 3 , –OCH 2 CH 3 , –CH 2 OCH 3 , –NHCH 3 , –ONHCH 3 , –NHOCH 3 , –SCH 3 , –CH 2 NHCH 2 CH 3 , and –NHCH 2 CH 2 CH 3 .
  • substituted heteroalkyl groups include, but are not limited to, –CH 2 NHC (O) CH 3 and –NHC (O) CH 2 CH 3 .
  • heteroalkylene and “heteroalkanediyl” are used interchangeably herein in reference to a linear or branched saturated divalent hydrocarbon radical that contains one or more heteroatoms in its main chain, each independently selected from O, S, and N.
  • the heteroalkylene is optionally substituted with one or more substituents Q as described herein.
  • C 1-6 heteroalkylene refers to a linear saturated divalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the heteroalkylene is a linear saturated divalent hydrocarbon radical that has 1 to 30 (C 1-30 ) , 1 to 20 (C 1-20 ) , 1 to 15 (C 1-15 ) , 1 to 10 (C 1-10 ) , or 1 to 6 (C 1-6 ) carbon atoms, or branched saturated divalent hydrocarbon radical of 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3-6 ) carbon atoms.
  • linear C 1-6 and branched C 3-6 heteroalkylene groups are also referred as “lower heteroalkylene.
  • heteroalkylene groups include, but are not limited to, –CH 2 O–, – (CH 2 ) 2 O–, – (CH 2 ) 3 O–, – (CH 2 ) 4 O–, – (CH 2 ) 5 O–, – (CH 2 ) 6 O–, – (CH 2 ) 7 O–, – (CH 2 ) 8 O–, – (CH 2 ) 9 O–, – (CH 2 ) 10 O–, –CH 2 OCH 2 –, – (CH 2 CH 2 O) 2 –, – (CH 2 CH 2 O) 3 –, – (CH 2 CH 2 O) 4 –, – (CH 2 CH 2 O) 5 –, –CH 2 NH—, –CH 2 NHCH 2 –, –CH 2 CH 2 NH–, –CH 2 S–, –CH 2 SCH 2 –, and –CH 2 CH 2 S–.
  • substituted heteroalkylene groups include, but are not limited to, –C (O) CH 2 O–, –C (O) (CH 2 ) 2 O–, –C (O) (CH 2 ) 3 O–, –C (O) (CH 2 ) 4 O–, –C (O) (CH 2 ) 5 O–, –C (O) (CH 2 ) 6 O–, –C (O) (CH 2 ) 7 O–, –C (O) (CH 2 ) 8 O–, –C (O) (CH 2 ) 9 O–, –C (O) (CH 2 ) 10 O–, –C (O) CH 2 OCH 2 CH 2 O–, –C (O) CH 2 O (CH 2 CH 2 O) 2 –, –C (O) CH 2 O (CH 2 CH 2 O) 3 —, –C (O) CH 2 O (CH 2 CH 2 O) 4 , –C (O) CH 2 O (CH 2 CH 2 O) 5
  • alkenyl refers to a linear or branched monovalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon double bond (s) .
  • the alkenyl is optionally substituted with one or more substituents Q as described herein.
  • alkenyl embraces radicals having a “cis” or “trans” configuration or a mixture thereof, or alternatively, a “Z” or “E” configuration or a mixture thereof, as appreciated by those of ordinary skill in the art.
  • C 2-6 alkenyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the alkenyl is a linear monovalent hydrocarbon radical of 2 to 30 (C 2-30 ) , 2 to 20 (C 2-20 ) , 2 to 15 (C 2-15 ) , 2 to 10 (C 2-10 ) , or 2 to 6 (C 2-6 ) carbon atoms, or a branched monovalent hydrocarbon radical of 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3-6 ) carbon atoms.
  • alkenyl groups include, but are not limited to, ethenyl, propenyl (including all isomeric forms, e.g., propen-1-yl, propen-2-yl, and allyl) , and butenyl (including all isomeric forms, e.g., buten-1-yl, buten-2-yl, buten-3-yl, and 2-buten-1-yl) .
  • alkenylene and “alkenediyl” are used interchangeably herein in reference to a linear or branched divalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon double bond (s) .
  • the alkenylene is optionally substituted with one or more substituents Q as described herein.
  • alkenylene embraces radicals having a “cis” or “trans” configuration or a mixture thereof, or alternatively, a “Z” or “E” configuration or a mixture thereof, as appreciated by those of ordinary skill in the art.
  • C 2-6 alkenylene refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the alkenylene is a linear divalent hydrocarbon radical of 2 to 30 (C 2-30 ) , 2 to 20 (C 2-20 ) , 2 to 15 (C 2-15 ) , 2 to 10 (C 2-10 ) , or 2 to 6 (C 2-6 ) carbon atoms, or a branched divalent hydrocarbon radical of 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3-6 ) carbon atoms.
  • alkenylene groups include, but are not limited to, ethenediyl (including all isomeric forms, e.g., ethene-1, 1-diyl and ethene-1, 2-diyl) , propenediyl (including all isomeric forms, e.g., 1-propene-1, 1-diyl, 1-propene-1, 2-diyl, and 1-propene-1, 3-diyl) , butenediyl (including all isomeric forms, e.g., 1-butene-1, 1-diyl, 1-butene-1, 2-diyl, 1-butene-1, 3-diyl, and 1-butene-1, 4-diyl) , pentenediyl (including all isomeric forms, e.g., 1-pentene-1, 1-diyl, 1-pentene-1, 2-diyl, 1-pentene-1, 3-diyl, 1-pentene-1, 4-
  • heteroalkenyl refers to a linear or branched monovalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon double bond (s) , and which contains one or more heteroatoms on its main chain, each independently selected from O, S, and N.
  • the heteroalkenyl is optionally substituted with one or more substituents Q as described herein.
  • the term “heteroalkenyl” embraces radicals having a “cis” or “trans” configuration or a mixture thereof, or alternatively, a “Z” or “E” configuration or a mixture thereof, as appreciated by those of ordinary skill in the art.
  • C 2-6 heteroalkenyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the heteroalkenyl is a linear monovalent hydrocarbon radical that has 2 to 30 (C 2-30 ) , 2 to 20 (C 2-20 ) , 2 to 15 (C 2-15 ) , 2 to 10 (C 2-10 ) , or 2 to 6 (C 2-6 ) carbon atoms, or branched monovalent hydrocarbon radical of 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3-6 ) carbon atoms.
  • linear C 2-6 and branched C 3-6 heteroalkenyl groups are also referred as “lower heteroalkenyl. ”
  • heteroalkenylene and “heteroalkenediyl” are used interchangeably herein in reference to a linear or branched divalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon double bond (s) , and which contains one or more heteroatoms each independently selected from O, S, and N in the hydrocarbon chain.
  • the heteroalkenylene is optionally substituted with one or more substituents Q as described herein.
  • heteroalkenylene embraces radicals having a “cis” or “trans” configuration or a mixture thereof, or alternatively, a “Z” or “E” configuration or a mixture thereof, as appreciated by those of ordinary skill in the art.
  • C 2-6 heteroalkenylene refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the heteroalkenylene is a linear divalent hydrocarbon radical of 2 to 30 (C 2-30 ) , 2 to 20 (C 2-20 ) , 2 to 15 (C 2-15 ) , 2 to 10 (C 2-10 ) , or 2 to 6 (C 2-6 ) carbon atoms, or a branched divalent hydrocarbon radical of 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3-6 ) carbon atoms.
  • alkynyl refers to a linear or branched monovalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon triple bond (s) .
  • An alkynyl group may additionally contain one or more carbon-carbon double bond (s) .
  • the alkynyl is optionally substituted with one or more substituents Q as described herein.
  • C 2-6 alkynyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent hydrocarbon radical of 4 to 6 carbon atoms.
  • the alkynyl is a linear monovalent hydrocarbon radical of 2 to 30 (C 2-30 ) , 2 to 20 (C 2-20 ) , 2 to 15 (C 2-15 ) , 2 to 10 (C 2-10 ) , or 2 to 6 (C 2-6 ) carbon atoms, or a branched monovalent hydrocarbon radical of 4 to 30 (C 4-30 ) , 4 to 20 (C 4-20 ) , 4 to 15 (C 4-15 ) , 4 to 10 (C 4-10 ) , or 4 to 6 (C 4-6 ) carbon atoms.
  • alkynyl groups include, but are not limited to, ethynyl (–C ⁇ CH) , propynyl (including all isomeric forms, e.g., 1-propynyl (–C ⁇ CCH 3 ) and propargyl (–CH 2 C ⁇ CH) ) , butynyl (including all isomeric forms, e.g., 1-butyn-1-yl and 2-butyn-1-yl) , pentynyl (including all isomeric forms, e.g., 1-pentyn-1-yl and 1-methyl-2-butyn-1-yl) , and hexynyl (including all isomeric forms, e.g., 1-hexyn-1-yl and 2-hexyn-1-yl) .
  • alkynylene and “alkynediyl” are used interchangeably herein in reference to a linear or branched divalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon triple bond (s) .
  • An alkynylene group may additionally contain one or more carbon-carbon double bond (s) .
  • the alkynylene is optionally substituted with one or more substituents Q as described herein.
  • C 2-6 alkynylene refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon radical of 4 to 6 carbon atoms.
  • the alkynylene is a linear divalent hydrocarbon radical of 2 to 30 (C 2-30 ) , 2 to 20 (C 2-20 ) , 2 to 15 (C 2-15 ) , 2 to 10 (C 2-10 ) , or 2 to 6 (C 2-6 ) carbon atoms, or a branched divalent hydrocarbon radical of 4 to 30 (C 4-30 ) , 4 to 20 (C 4-20 ) , 4 to 15 (C 4-15 ) , 4 to 10 (C 4-10 ) , or 4 to 6 (C 4-6 ) carbon atoms.
  • alkynylene groups include, but are not limited to, ethynediyl, propynediyl (including all isomeric forms, e.g., 1-propyne-1, 3-diyl and 1-propyne-3, 3-diyl) , butynediyl (including all isomeric forms, e.g., 1-butyne-1, 3-diyl, 1-butyne-1, 4-diyl, and 2-butyne-1, 1-diyl) , pentynediyl (including all isomeric forms, e.g., 1-pentyne-1, 3-diyl, 1-pentyne-1, 4-diyl, and 2-pentyne-1, 1-diyl) , and hexynediyl (including all isomeric forms, e.g., 1-hexyne-1, 3-diyl, 1-hexyne-1,
  • heteroalkynyl refers to a linear or branched monovalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon triple bond (s) , and which contains one or more heteroatoms on its main chain, each independently selected from O, S, and N.
  • a heteroalkynyl group may additionally contain a carbon-carbon double bond.
  • the heteroalkynyl is optionally substituted with one or more substituents Q as described herein.
  • C 2-6 heteroalkynyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the heteroalkynyl is a linear monovalent hydrocarbon radical that has 2 to 30 (C 2-30 ) , 2 to 20 (C 2-20 ) , 2 to 15 (C 2-15 ) , 2 to 10 (C 2-10 ) , or 2 to 6 (C 2-6 ) carbon atoms, or branched monovalent hydrocarbon radical of 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3-6 ) carbon atoms.
  • linear C 2-6 and branched C 3-6 heteroalkynyl groups are also referred as “lower heteroalkynyl. ”
  • heteroalkynyl groups include, but are not limited to, –OCH 2 C ⁇ CH, –SCH 2 C ⁇ CH, or –NHCH 2 C ⁇ CH.
  • heteroalkynylene and “heteroalkynediyl” are used interchangeably herein in reference to a linear or branched divalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon triple bond (s) , and which contains one or more heteroatoms in its main chain, each independently selected from O, S, and N.
  • a heteroalkynylene group may additionally contain a carbon-carbon double bond.
  • the heteroalkynylene is optionally substituted with one or more substituents Q as described herein.
  • C 2-6 heteroalkynylene refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon radical of 4 to 6 carbon atoms.
  • the heteroalkynylene is a linear divalent hydrocarbon radical of 2 to 30 (C 2-30 ) , 2 to 20 (C 2-20 ) , 2 to 15 (C 2-15 ) , 2 to 10 (C 2-10 ) , or 2 to 6 (C 2-6 ) carbon atoms, or a branched divalent hydrocarbon radical of 4 to 30 (C 4-30 ) , 4 to 20 (C 4-20 ) , 4 to 15 (C 4-15 ) , 4 to 10 (C 4-10 ) , or 4 to 6 (C 4-6 ) carbon atoms.
  • heteroalkynylene groups include, but are not limited to, –C ⁇ CCH 2 O–, –C ⁇ CCH 2 S–, or –C ⁇ CCH 2
  • halogen, ” “halide, ” or “halo” refers to fluoro (F) , chloro (Cl) , bromo (Br) , and iodo (I) . Therefore, the term “haloalkyl” refers to the alkyl as mentioned above, which is substituted with one or more halo, such as F, Br, Cl, and I, the term “haloalkenyl” refers to the alkyl as mentioned above, which is substituted with one or more halo, such as F, Br, Cl, and I, and the term “haloalkynyl” refers to the alkyl as mentioned above, which is substituted with one or more halo, such as F, Br, Cl, and I.
  • cycloalkyl refers to a cyclic monovalent hydrocarbon radical, which is optionally substituted with one or more substituents Q as described herein.
  • the cycloalkyl is a saturated or unsaturated but non-aromatic, and/or bridged or non-bridged, and/or fused bicyclic group.
  • the cycloalkyl has from 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , from 3 to 15 (C 3-15 ) , from 3 to 10 (C 3-10 ) , or from 3 to 7 (C 3-7 ) carbon atoms.
  • the cycloalkyl is monocyclic.
  • the cycloalkyl is bicyclic. In yet another embodiment, the cycloalkyl is tricyclic. In still another embodiment, the cycloalkyl is polycyclic. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptenyl, bicyclo [1.1.1] pentyl, bicyclo [2.1.1] hexyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl, decalinyl, and adamantyl.
  • cycloalkylene and “cycloalkanediyl” are used interchangeably herein in reference to a cyclic divalent hydrocarbon radical, which may be optionally substituted with one or more substituents Q as described herein.
  • cycloalkylene groups may be saturated or unsaturated but non-aromatic, and/or bridged, and/or non-bridged, and/or fused bicyclic groups.
  • the cycloalkylene has from 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , from 3 to 15 (C 3-15 ) , from 3 to 10 (C 3-10 ) , or from 3 to 7 (C 3-7 ) carbon atoms.
  • cycloalkylene groups include, but are not limited to, cyclopropanediyl (including all isomeric forms, e.g., cyclopropane-1, 1-diyl and cyclopropane-1, 2-diyl) , cyclobutanediyl (including all isomeric forms, e.g., cyclobutane-1, 1-diyl, cyclobutane-1, 2-diyl, and cyclobutane-1, 3-diyl) , cyclopentanediyl (including all isomeric forms, e.g., cyclopentane-1, 1-diyl, cyclopentane-1, 2-diyl, and cyclopentane-1, 3-diyl) , cyclohexanediyl (including all isomeric forms, e.g., cyclohexane-1, 1-diyl, cyclohexane
  • heterocyclyl refers to a monovalent monocyclic non-aromatic ring system or monovalent polycyclic ring system that contains at least one non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms, each independently selected from O, S, and N; and the remaining ring atoms are carbon atoms.
  • heterocyclyl group containing a heteroaromatic ring and a nonaromatic heterocyclic ring, the heterocyclyl group is not bonded to the rest of a molecule through the heteroaromatic ring.
  • the heterocyclyl or heterocyclic group has from 3 to 20, from 3 to 15, from 3 to 10, from 3 to 8, from 4 to 7, or from 5 to 6 ring atoms.
  • the heterocyclyl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may be fused or bridged, and in which nitrogen or sulfur atoms may be optionally oxidized, nitrogen atoms may be optionally quaternized, and some rings may be partially or fully saturated, or aromatic.
  • the heterocyclyl may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound.
  • heterocyclyls and heterocyclic groups include, but are not limited to, azepinyl, benzodioxanyl, benzodioxolyl, benzofuranonyl, chromanyl, decahydroisoquinolinyl, dihydrobenzofuranyl, dihydrobenzisothiazolyl, dihydro-benzisoxazinyl (including all isomeric forms, e.g., 1, 4-dihydrobenzo [d] [1, 3] oxazinyl, 3, 4-dihydrobenzo [c] [1, 2] -oxazinyl, and 3, 4-dihydrobenzo [d] [1, 2] oxazinyl) , dihydrobenzothienyl, dihydroisobenzofuranyl, dihydrobenzo [c] thienyl, dihydrofuryl, dihydroisoindolyl, dihydro-pyranyl, dihydropyrany
  • heterocyclylene refers to a divalent monocyclic non-aromatic ring system or divalent polycyclic ring system that contains at least one non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms independently selected from O, S, and N; and the remaining ring atoms are carbon atoms.
  • the heterocyclylene group For a heterocyclylene group containing a heteroaromatic ring and a nonaromatic heterocyclic ring, the heterocyclylene group has at least one bond to the rest of a molecule via its nonaromatic heterocyclic ring.
  • the heterocyclylene group has from 3 to 20, from 3 to 15, from 3 to 10, from 3 to 8, from 4 to 7, or from 5 to 6 ring atoms.
  • the heterocyclylene is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may be fused or bridged, and in which nitrogen or sulfur atoms may be optionally oxidized, nitrogen atoms may be optionally quaternized, and some rings may be partially or fully saturated, or aromatic.
  • the heterocyclylene may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound.
  • heterocyclylene groups include, but are not limited to, azepindiyl, benzodioxandiyl, benzodioxoldiyl, benzofuranondiyl, chromandiyl, decahydroisoquinolindiyl, dihydrobenzofurandiyl, dihydrobenzisothiazoldiyl, dihydrobenzisoxazindiyl (including all isomeric forms, e.g., 1, 4-dihydrobenzo [d] [1, 3] oxazindiyl, 3, 4-dihydrobenzo [c] [1, 2] oxazindiyl, and 3, 4-dihydrobenzo [d] [1, 2] oxazindiyl) , dihydrobenzothiendiyl, dihydroisobenzofurandiyl, dihydrobenzo [c] thiendiyl, dihydrofurdiyl, dihydroisoiso
  • aryl refers to a monovalent monocyclic aromatic hydrocarbon radical and/or monovalent polycyclic aromatic hydrocarbon radical that contain at least one aromatic carbon ring.
  • the aryl has from 6 to 18 (C 6-18 ) , from 6 to 14 (C 6-14 ) , or from 6 to 10 (C 6-10 ) ring carbon atoms.
  • Examples of aryl groups include, but are not limited to, phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, pyrenyl, biphenyl, and terphenyl.
  • the aryl also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for example, dihydronaphthyl, indenyl, indanyl, or tetrahydronaphthyl (tetralinyl) .
  • the aryl is monocyclic.
  • the aryl is bicyclic.
  • the aryl is tricyclic.
  • the aryl is polycyclic.
  • the aryl is optionally substituted with one or more substituents Q as described herein.
  • arylene and “arenediyl” are used interchangeably herein in reference to a divalent monocyclic aromatic hydrocarbon radical or divalent polycyclic aromatic hydrocarbon radical that contains at least one aromatic hydrocarbon ring.
  • the arylene has from 6 to 18 (C 6-18 ) , from 6 to 14 (C 6-14 ) , or from 6 to 10 (C 6-10 ) ring atoms.
  • arylene groups include, but are not limited to, phenylene (including all isomeric forms, e.g., phen-1, 2-diyl, phen-1, 3-diyl, and phen-1, 4-diyl) , naphthylene (including all isomeric forms, e.g., naphth-1, 2-diyl, naphth-1, 3-diyl, and naphth-1, 8-diyl) , fluorenylene (including all isomeric forms, e.g., fluoren-1, 2-diyl, fluoren-1, 3-diyl, and fluoren-1, 8-diyl) , azulenylene (including all isomeric forms, e.g., azulen-1, 2-diyl, azulen-1, 3-diyl, and azulen-1, 8-diyl) , anthrylene (including all isomeric forms, e.
  • Arylene also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for example, dihydronaphthylene (including all isomeric forms, e.g., dihydronaphth-1, 2-diyl and dihydronaphth-1, 8-diyl) , indenylene (including all isomeric forms, e.g., inden-1, 2-diyl, inden-1, 5-diyl, and inden-1, 7-diyl) , indanylene (including all isomeric forms, e.g., indan-1, 2-diyl, indan-1, 5-diyl, and indan-1, 7-diyl) , or tetrahydronaphthylene (tetralinylene) (including all isomeric forms, e.g., tetrahydronaphth-1, 2-di
  • aralkyl or “arylalkyl” refers to a monovalent alkyl group substituted with one or more aryl groups. In certain embodiments, the aralkyl has from 7 to 30 (C 7-30 ) , from 7 to 20 (C 7-20 ) , or from 7 to 15 (C 7-15 ) carbon atoms.
  • aralkyl groups include, but are not limited to, benzyl, phenylethyl (including all isomeric forms, e.g., 1-phenylethyl and 2-phenylethyl) , and phenylpropyl (including all isomeric forms, e.g., 1-phenylpropyl, 2-phenylpropyl, and 3-phenylpropyl) .
  • the aralkyl is optionally substituted with one or more substituents Q as described herein.
  • aralkylene or “arylalkylene” refers to a divalent alkyl group substituted with one or more aryl groups. In certain embodiments, the aralkylene has from 7 to 30 (C 7-30 ) , from 7 to 20 (C 7-20 ) , or from 7 to 15 (C 7-15 ) carbon atoms.
  • aralkylene groups include, but are not limited to, benzylene (including all isomeric forms, e.g., phenylmethdiyl) , phenylethylene (including all isomeric forms, e.g., 2-phenyl-ethan-1, 1-diyl and 2-phenyl-ethan-1, 2-diyl) , and phenylpropylene (including all isomeric forms, e.g., 3-phenyl-propan-1, 1-diyl, 3-phenyl-propan-1, 2-diyl, and 3-phenyl-propan-1, 3-diyl) .
  • the aralkylene is optionally substituted with one or more substituents Q as described herein.
  • heteroaryl refers to a monovalent monocyclic aromatic group or monovalent polycyclic aromatic group that contain at least one aromatic ring, wherein at least one aromatic ring contains one or more heteroatoms, each independently selected from O, S, and N, in the ring.
  • heteroaryl group containing a heteroaromatic ring and a nonaromatic heterocyclic ring the heteroaryl group is not bonded to the rest of a molecule through its nonaromatic heterocyclic ring.
  • Each ring of a heteroaryl group can contain one or two O atoms, one or two S atoms, and/or one to four N atoms; provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom.
  • the heteroaryl has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms.
  • the heteroaryl is monocyclic.
  • heteroaryl groups examples include, but are not limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl, and triazolyl.
  • the heteroaryl is bicyclic.
  • bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, furopyrindyl (including all isomeric forms, e.g., furo [2, 3-b] pyridinyl, furo [2, 3-c] pyridinyl, furo [3, 2-b] pyridinyl, furo [3, 2-c] pyridinyl, furo [3, 4-b] pyridinyl, and furo [3, 4-c] pyridinyl) , imidazopyridinyl (including all isomeric forms, e.g., imidazo [1, 2-a] pyridinyl, imidazo [4, 5-b] pyridinyl, and imidazo [4, 5-c] pyridinyl
  • the heteroaryl is tricyclic.
  • tricyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, perimidinyl, phenanthrolinyl, phenanthridinyl (including all isomeric forms, e.g., 1, 5-phenanthrolinyl, 1, 6-phenanthrolinyl, 1, 7-phenanthrolinyl, 1, 9-phenanthrolinyl, and 2, 10-phenanthrolinyl) , phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and xanthenyl.
  • the heteroaryl is optionally substituted with one or more substituents Q as described herein.
  • heteroarylene and “heteroarenediyl” are used interchangeably herein in reference to a divalent monocyclic aromatic group or divalent polycyclic aromatic group that contains at least one aromatic ring, wherein at least one aromatic ring contains one or more heteroatoms in the ring, each of which is independently selected from O, S, and N.
  • heteroarylene group containing a heteroaromatic ring and a nonaromatic heterocyclic ring the heteroarylene group is not bonded to the rest of a molecule via its nonaromatic heterocyclic ring.
  • Each ring of a heteroarylene group can contain one or two O atoms, one or two S atoms, and/or one to four N atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom.
  • the heteroarylene has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms.
  • Examples of monocyclic heteroarylene groups include, but are not limited to, furandiyl, imidazoldiyl, isothiazoldiyl, isoxazoldiyl, oxadiazoldiyl, oxazoldiyl, pyrazindiyl, pyrazoldiyl, pyridazindiyl, pyridindiyl, pyrimidindiyl, pyrroldiyl, thiadiazoldiyl, thiazoldiyl, thiendiyl, tetrazoldiyl, triazinediyl, and triazoldiyl.
  • bicyclic heteroarylene groups include, but are not limited to, benzofurandiyl, benzimidazoldiyl, benzoisoxazoldiyl, benzopyrandiyl, benzothiadiazoldiyl, benzothiazoldiyl, benzothiendiyl, benzotriazoldiyl, benzoxazoldiyl, furopyridindiyl (including all isomeric forms, e.g., furo [2, 3-b] pyridindiyl, furo [2, 3-c] pyridindiyl, furo [3, 2-b] pyridindiyl, furo [3, 2-c] -pyridindiyl, furo [3, 4-b] pyridindiyl, and furo [3, 4-c] pyridindiyl) , imidazopyridindiyl (including all isomeric forms, e.g., imidazo [1, 2-a] pyrid
  • tricyclic heteroarylene groups include, but are not limited to, acridindiyl, benzindoldiyl, carbazoldiyl, dibenzofurandiyl, perimidindiyl, phenanthrolindiyl (including all isomeric forms, e.g., 1, 5-phenanthrolindiyl, 1, 6-phenanthrolindiyl, 1, 7-phenanthrolindiyl, 1, 9-phenanthrolindiyl, and 2, 10-phenanthrolindiyl) , phenanthridindiyl, phenarsazindiyl, phenazindiyl, phenothiazindiyl, phenoxazindiyl, and xanthendiyl.
  • heteroarylene is optionally substituted with one or more substituents Q as described herein.
  • heteroarylalkyl refers to a monovalent alkyl group substituted with one or more heteroaryl groups.
  • the heteroarylalkyl has from 6 to 21 (C 6-21 ) , from 6 to 16 (C 6-16 ) , or from 6 to 11 (C 6-11 ) carbon atoms.
  • heteroarylalkyl groups include, but are not limited to, furanylmethyl, imidazolylmethyl, isothiazolylmethyl, isoxazolylmethyl, oxadiazolylmethyl, oxazolylmethyl, pyrazinylmethyl, pyrazolylmethyl, pyridazinylmethyl, pyridylmethyl, pyrimidinylmethyl, pyrrolylmethyl, thiadiazolylmethyl, thiazolylmethyl, thienylmethyl, tetrazolylmethyl, triazinylmethyl, and triazolylmethyl.
  • the heteroarylalkyl is optionally substituted with one or more substituents Q as described herein.
  • each Q a is independently selected from: (a) deuterium, cyano, halo, imino, nitro, and oxo; (b) C 1-6 alkyl, C 1-6 heteroalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, and heterocyclyl; and (c) –C (O) R e , –C (O) OR e , –C (O) NR f R g , –C (O) SR e , –C (NR e ) NR f R g , –C (S) R e , –C (S) OR e , –C (S) NR f R g , –OR e , –OC (O) R e , –OC (O) OR e , –OC (O)
  • optically active and ” enantiomerically active refer to a collection of molecules, which has an enantiomeric excess of no less than about 80%, no less than about 90%, no less than about 91%, no less than about 92%, no less than about 93%, no less than about 94%, no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
  • an optically active compound comprises about 95%or more of one enantiomer and about 5%or less of the other enantiomer based on the total weight of the enantiomeric mixture in question.
  • an optically active compound comprises about 98%or more of one enantiomer and about 2%or less of the other enantiomer based on the total weight of the enantiomeric mixture in question. In certain embodiments, an optically active compound comprises about 99%or more of one enantiomer and about 1%or less of the other enantiomer based on the total weight of the enantiomeric mixture in question.
  • R and S are used to denote the absolute configuration of the compound about its chiral center (s) .
  • the (+) and (-) are used to denote the optical rotation of the compound, that is, the direction in which a plane of polarized light is rotated by the optically active compound.
  • the (-) prefix indicates that the compound is levorotatory, that is, the compound rotates the plane of polarized light to the left or counterclockwise.
  • the (+) prefix indicates that the compound is dextrorotatory, that is, the compound rotates the plane of polarized light to the right or clockwise.
  • the sign of optical rotation, (+) and (-) is not related to the absolute configuration of the compound, R andS.
  • isotopically enriched refers to a compound that contains an unnatural proportion of an isotope at one or more of the atoms that constitute such a compound.
  • an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen ( 1 H) , deuterium ( 2 H) , tritium ( 3 H) , carbon-11 ( 11 C) , carbon-12 ( 12 C) , carbon-13 ( 13 C) , carbon-14 ( 14 C) , nitrogen-13 ( 13 N) , nitrogen-14 ( 14 N) , nitrogen-15 ( 15 N) , oxygen-14 ( 14 O) , oxygen-15 ( 15 O) , oxygen-16 ( 16 O) , oxygen-17 ( 17 O) , oxygen-18 ( 18 O) , fluorine-17 ( 17 F) , fluorine-18 ( 18 F) , phosphorus-31 ( 31 P) , phosphorus-32 ( 32 P) , phosphorus-33 ( 33 P) , sulfur-
  • an isotopically enriched compound is in a stable form, that is, non-radioactive.
  • an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen ( 1 H) , deuterium ( 2 H) , carbon-12 ( 12 C) , carbon-13 ( 13 C) , nitrogen-14 ( 14 N) , nitrogen-15 ( 15 N) , oxygen-16 ( 16 O) , oxygen-17 ( 17 O) , oxygen-18 ( 18 O) , fluorine-17 ( 17 F) , phosphorus-31 ( 31 P) , sulfur-32 ( 32 S) , sulfur-33 ( 33 S) , sulfur-34 ( 34 S) , sulfur-36 ( 36 S) , chlorine-35 ( 35 Cl) , chlorine-37 ( 37 Cl) , bromine-79 ( 79 Br) , bromine-81 ( 81 Br) , and iodine-127 ( 127 I) .
  • an isotopically enriched compound is in an unstable form, that is, radioactive.
  • an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, tritium ( 3 H) , carbon-11 ( 11 C) , carbon-14 ( 14 C) , nitrogen-13 ( 13 N) , oxygen-14 ( 14 O) , oxygen-15 ( 15 O) , fluorine-18 ( 18 F) , phosphorus-32 ( 32 P) , phosphorus-33 ( 33 P) , sulfur-35 ( 35 S) , chlorine-36 ( 36 Cl) , iodine-123 ( 123 I) , iodine-125 ( 125 I) , iodine-129 ( 129 I) , and iodine-131 ( 131 I) .
  • any hydrogen can be 2 H, as example, or any carbon can be 13 C, as example, or any nitrogen can be 15 N, as example, or any oxygen can be 18 O, as example, where feasible according to the judgment of one of ordinary skill in the art.
  • isotopic enrichment refers to the percentage of incorporation of a less prevalent isotope (e.g., D for deuterium or hydrogen-2) of an element at a given position in a molecule in the place of a more prevalent isotope (e.g., 1 H for protium or hydrogen-1) of the element.
  • a less prevalent isotope e.g., D for deuterium or hydrogen-2
  • a more prevalent isotope e.g., 1 H for protium or hydrogen-1
  • isotopic enrichment factor refers to the ratio between the isotopic abundance in an isotopically enriched compound and the natural abundance of a specific isotope.
  • hydrogen refers to the composition of naturally occurring hydrogen isotopes, which include protium ( 1 H) , deuterium ( 2 H or D) , and tritium ( 3 H) , in their natural abundances.
  • Protium is the most common hydrogen isotope having a natural abundance of more than 99.98%.
  • Deuterium is a less prevalent hydrogen isotope having a natural abundance of about 0.0156%.
  • deuterium enrichment refers to the percentage of incorporation of deuterium at a given position in a molecule in the place of hydrogen. For example, deuterium enrichment of 1%at a given position means that 1%of molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156%on average, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156%on average. As used herein, when a particular position in an isotopically enriched compound is designated as having deuterium, it is understood that the abundance of deuterium at that position in the compound is substantially greater than its natural abundance (0.0156%) .
  • carbon or the symbol “C” refers to the composition of naturally occurring carbon isotopes, which include carbon-12 ( 12 C) and carbon-13 ( 13 C) in their natural abundances.
  • Carbon-12 is the most common carbon isotope having a natural abundance of more than 98.89%.
  • Carbon-13 is a less prevalent carbon isotope having a natural abundance of about 1.11%.
  • carbon-13 enrichment or “ 13 C enrichment” refers to the percentage of incorporation of carbon-13 at a given position in a molecule in the place of carbon.
  • carbon-13 enrichment of 10%at a given position means that 10%of molecules in a given sample contain carbon-13 at the specified position. Because the naturally occurring distribution of carbon-13 is about 1.11%on average, carbon-13 enrichment at any position in a compound synthesized using non-enriched starting materials is about 1.11%on average.
  • when a particular position in an isotopically enriched compound is designated as having carbon-13, it is understood that the abundance of carbon-13 at that position in the compound is substantially greater than its natural abundance (1.11%) .
  • substantially pure and substantially homogeneous mean, when referred to a substance, sufficiently homogeneous to appear free of readily detectable impurities as determined by a standard analytical method used by one of ordinary skill in the art, including, but not limited to, thin layer chromatography (TLC) , gel electrophoresis, high performance liquid chromatography (HPLC) , gas chromatography (GC) , nuclear magnetic resonance (NMR) , and mass spectrometry (MS) ; or sufficiently pure such that further purification would not detectably alter the physical, chemical, biological, and/or pharmacological properties, such as enzymatic and biological activities, of the substance.
  • TLC thin layer chromatography
  • HPLC high performance liquid chromatography
  • GC gas chromatography
  • NMR nuclear magnetic resonance
  • MS mass spectrometry
  • substantially pure or “substantially homogeneous” refers to a collection of molecules, wherein at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.5%by weight of the molecules are a single compound, including a single enantiomer, a racemic mixture, or a mixture of enantiomers, as determined by standard analytical methods.
  • a molecule that contains other than the designated isotope at the specified position is an impurity with respect to the isotopically enriched compound.
  • a deuterated compound that has an atom at a particular position designated as deuterium a compound that contains a protium at the same position is an impurity.
  • solvate refers to a complex or aggregate formed by one or more molecules of a solute, e.g., a compound provided herein, and one or more molecules of a solvent, which are present in a stoichiometric or non-stoichiometric amount.
  • Suitable solvents include, but are not limited to, water, methanol, ethanol, n-propanol, isopropanol, and acetic acid.
  • the solvent is pharmaceutically acceptable.
  • the complex or aggregate is in a crystalline form.
  • the complex or aggregate is in a noncrystalline form.
  • the solvent is water
  • the solvate is a hydrate. Examples of hydrates include, but are not limited to, a hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate, and pentahydrate.
  • an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof” has the same meaning as the phrase “ (i) an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant of the compound referenced therein; (ii) a pharmaceutically acceptable salt, solvate, hydrate, or prodrug of the compound referenced therein; or (iii) a pharmaceutically acceptable salt, solvate, hydrate, or prodrug of an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of a
  • a compound of Formula (I) or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; wherein, is a single bond or a double bond;R 1 is (i) hydrogen, deuterium, or halo; (ii) C 1-6 alkyl, or C 1-6 haloalkyl; or (iii) 5-to 6-membered heteroaryl, which is optionally substituted with OH, or NH 2 ;R 2 is (i) hydrogen, deuterium, or halo; (ii) C 1-6 alkyl, or C 1-6 haloalkyl; or (iii) 5-to 6-membered heteroaryl, which is optionally substituted with OH,
  • R 1 is hydrogen. In certain embodiments, R 1 is deuterium. In certain embodiments, R 1 is halo. In certain embodiments, R 1 is C 1-6 alkyl. In certain embodiments, R 1 is C 1-6 haloalkyl. In certain embodiments, R 1 is 5-to 6-membered heteroaryl, which is optionally substituted with OH. In certain embodiments, R 1 is 5-to 6-membered heteroaryl, which is optionally substituted with NH 2 .
  • R 2 is hydrogen. In certain embodiments, R 2 is deuterium. In certain embodiments, R 2 is halo. In certain embodiments, R 2 is C 1-6 alkyl. In certain embodiments, R 2 is C 1-6 haloalkyl. In certain embodiments, R 2 is 5-to 6-membered heteroaryl, which is optionally substituted with OH. In certain embodiments, R 2 is 5-to 6-membered heteroaryl, which is optionally substituted with NH 2 . In certain embodiments, R 2 is 6-membered heteroaryl, such as pyridyl, which is optionally substituted with OH. In certain embodiments, R 2 is 6-membered heteroaryl, such as pyridyl, which is optionally substituted with NH 2 .
  • At least one of R 1 and R 2 is 5-to 6-membered heteroaryl, which is optionally substituted with OH, or NH 2 . In certain embodiments, at least one of R 1 and R 2 is 5-to 6-membered heteroaryl, which is optionally substituted with NH 2 .
  • R 3 is hydrogen. In certain embodiments, R 3 is deuterium. In certain embodiments, R 3 is halo. In certain embodiments, R 3 is C 1-6 alkyl. In certain embodiments, R 3 is C 1-6 haloalkyl.
  • R 4 is hydrogen. In certain embodiments, R 4 is C 1-6 alkyl. In certain embodiments, R 4 is C 1-6 haloalkyl. In certain embodiments, R 4 is C 2-6 alkenyl. In certain embodiments, R 4 is C 2-6 haloalkenyl. In certain embodiments, R 4 is C 2-6 alkynyl. In certain embodiments, R 4 is C 2-6 haloalkynyl. In certain embodiments, R 4 is C 3-10 cycloalkyl. In certain embodiments, R 4 is 3-to 10-membered heterocyclyl. In certain embodiments, R 4 is C 6-14 aryl. In certain embodiments, R 4 is C 7-15 aralkyl.
  • R 4 is 5-to 10-membered heteroaryl. In certain embodiments, R 4 is 6-to 11-membered heteroarylalkyl. In certain embodiments, R 4 is–C (O) R 1a . In certain embodiments, R 4 is–C (O) OR 1a . In certain embodiments, R 4 is–C (O) NR 1b R 1c . In certain embodiments, R 4 is –C (O) SR 1a . In certain embodiments, R 4 is –C (NR 1a ) NR 1b R 1c . In certain embodiments, R 4 is –C (S) R 1a . In certain embodiments, R 4 is –C (S) OR 1a .
  • R 4 is –C (S) NR 1b R 1c . In certain embodiments, R 4 is –S (O) R 1a . In certain embodiments, R 4 is –S (O) 2 R 1a . In certain embodiments, R 4 is –S (O) NR 1b R 1c . In certain embodiments, R 4 is –S (O) 2 NR 1b R 1c .
  • R 5a is hydrogen. In certain embodiments, R 5a is deuterium. In certain embodiments, R 5a is cyano. In certain embodiments, R 5a is C 1-6 alkyl. In certain embodiments, R 5a is C 1-6 haloalkyl. In certain embodiments, R 5a is C 2-6 alkenyl. In certain embodiments, R 5a is C 2-6 haloalkenyl. In certain embodiments, R 5a is C 2-6 alkynyl. In certain embodiments, R 5a is C 2-6 haloalkynyl. In certain embodiments, R 5a is C 3-10 cycloalkyl. In certain embodiments, R 5a is 3-to 10-membered heterocyclyl.
  • R 5a is C 6-14 aryl. In certain embodiments, R 5a is C 7-15 aralkyl. In certain embodiments, R 5a is 5-to 10-membered heteroaryl. In certain embodiments, R 5a is 6-to 11-membered heteroarylalkyl.
  • R 5b is hydrogen. In certain embodiments, R 5b is deuterium. In certain embodiments, R 5b is cyano. In certain embodiments, R 5b is C 1-6 alkyl. In certain embodiments, R 5b is C 1-6 haloalkyl. In certain embodiments, R 5b is C 2-6 alkenyl. In certain embodiments, R 5b is C 2-6 haloalkenyl. In certain embodiments, R 5b is C 2-6 alkynyl. In certain embodiments, R 5b is C 2-6 haloalkynyl. In certain embodiments, R 5b is C 3-10 cycloalkyl. In certain embodiments, R 5b is 3-to 10-membered heterocyclyl.
  • R 5b is C 6-14 aryl. In certain embodiments, R 5b is C 7-15 aralkyl. In certain embodiments, R 5b is 5-to 10-membered heteroaryl. In certain embodiments, R 5b is 6-to 11-membered heteroarylalkyl.
  • R 5a1 is hydrogen. In certain embodiments, R 5a1 is deuterium. In certain embodiments, R 5a1 is cyano. In certain embodiments, R 5a1 is C 1-6 alkyl. In certain embodiments, R 5a1 is C 1-6 haloalkyl. In certain embodiments, R 5a1 is C 2-6 alkenyl. In certain embodiments, R 5a1 is C 2-6 haloalkenyl. In certain embodiments, R 5a1 is C 2-6 alkynyl. In certain embodiments, R 5a1 is C 2-6 haloalkynyl. In certain embodiments, R 5a1 is C 3-10 cycloalkyl.
  • R 5a1 is 3-to 10-membered heterocyclyl. In certain embodiments, R 5a1 is C 6-14 aryl. In certain embodiments, R 5a1 is C 7-15 aralkyl. In certain embodiments, R 5a1 is 5-to 10-membered heteroaryl. In certain embodiments, R 5a1 is 6-to 11-membered heteroarylalkyl.
  • R 5b1 is hydrogen. In certain embodiments, R 5b1 is deuterium. In certain embodiments, R 5b1 is cyano. In certain embodiments, R 5b1 is C 1-6 alkyl. In certain embodiments, R 5b1 is C 1-6 haloalkyl. In certain embodiments, R 5b1 is C 2-6 alkenyl. In certain embodiments, R 5b1 is C 2-6 haloalkenyl. In certain embodiments, R 5b1 is C 2-6 alkynyl. In certain embodiments, R 5b1 is C 2-6 haloalkynyl. In certain embodiments, R 5b1 is C 3-10 cycloalkyl.
  • R 5b1 is 3-to 10-membered heterocyclyl. In certain embodiments, R 5b1 is C 6-14 aryl. In certain embodiments, R 5b1 is C 7-15 aralkyl. In certain embodiments, R 5b1 is 5-to 10-membered heteroaryl. In certain embodiments, R 5b1 is 6-to 11-membered heteroarylalkyl.
  • R 5a and R 5b together with the carbon atom to which they are attached form C 3-10 cycloalkyl. In certain embodiments, R 5a and R 5b together with the carbon atom to which they are attached form 3-to 10-membered heterocyclyl.
  • R 5a1 and R 5b1 together with the carbon atom to which they are attached form C 3-10 cycloalkyl. In certain embodiments, R 5a1 and R 5b1 together with the carbon atom to which they are attached form 3-to 10-membered heterocyclyl.
  • E is O. In certain embodiments, E is S. In certain embodiments, E is NH.
  • W is N. In certain embodiments, W is CR 6’ .
  • R 6 is hydrogen. In certain embodiments, R 6 is deuterium. In certain embodiments, R 6 is cyano. In certain embodiments, R 6 is halo. In certain embodiments, R 6 is nitro. In certain embodiments, R 6 is C 1-6 alkyl. In certain embodiments, R 6 is C 1-6 haloalkyl. In certain embodiments, R 6 is C 2-6 alkenyl. In certain embodiments, R 6 is C 2-6 haloalkenyl. In certain embodiments, R 6 is C 2-6 alkynyl. In certain embodiments, R 6 is C 2-6 haloalkynyl.
  • R 6’ is hydrogen. In certain embodiments, R 6’ is deuterium. In certain embodiments, R 6’ is cyano. In certain embodiments, R 6’ is halo. In certain embodiments, R 6’ is nitro. In certain embodiments, R 6’ is C 1-6 alkyl. In certain embodiments, R 6’ is C 1-6 haloalkyl. In certain embodiments, R 6’ is C 2-6 alkenyl. In certain embodiments, R 6’ is C 2-6 haloalkenyl. In certain embodiments, R 6’ is C 2-6 alkynyl. In certain embodiments, R 6’ is C 2-6 haloalkynyl.
  • R 5b , and R 6’ are linked together so that form a 5-to 8-membered heterocyclyl.
  • R 5a , R 5b and R 6’ are linked together so that form a 5-to 10-membered heteroaryl.
  • each R 6a is independently (i) deuterium, cyano, halo, or nitro; (ii) C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, or C 2-6 haloalkynyl; (iii) C 1-6 heteroalkyl, C 2-6 heteroalkenyl, or C 2-6 heteroalkynyl, (iv) C 3-10 cycloalkyl, 3-to 10-membered heterocyclyl, C 6-14 aryl, C 7-15 aralkyl, 5-to 10-membered heteroaryl, or 6-to 11-membered heteroarylalkyl; or (v) –C (O) R 1a , –C (O) OR 1a , –C (O) NR 1b R 1c , –C (O) SR 1a , –C (NR 1a ) NR
  • b is an integer of 0, 1, 2, or 3. In certain embodiments, b is 0. In certain embodiments, b is 1. In certain embodiments, b is 2. In certain embodiments, b is 3.
  • A is a bond. In certain embodiments, A is C 2-6 alkenylene. In certain embodiments, A is C 3-10 cycloalkylene. In certain embodiments, A is C 6-14 arylene. In certain embodiments, A is 3-to 10-membered heterocyclylene. In certain embodiments, A is 5-to 10-membered heteroarylene.
  • A is C 3-10 cycloalkylene, which is optionally substituted with one or more substituents Q. In certain embodiments, A is C 6-14 arylene, which is optionally substituted with one or more substituents Q. In certain embodiments, A is C 5-6 cycloalkylene, which is optionally substituted with one or more substituents Q. In certain embodiments, A is C 6-10 arylene, which is optionally substituted with one or more substituents Q. In certain embodiments, A is C 6 cycloalkylene. In certain embodiments, A is cyclohexadiyl. In certain embodiments, A is cyclohexendiyl. In certain embodiments, A is phendiyl. In certain embodiments, A is phen-1, 4-diyl. In certain embodiments, A is optionally substituted with one or more substituents Q.
  • L is a linker optionally substituted with one or more substituents Q.
  • L has the structure of:–Z n – (R n –Z n ) z –wherein, the variables are as defined in the context.
  • each R n is independently C 1-20 alkylene, C 2-20 alkenylene, C 2-20 alkynylene, C 3-10 cycloalkylene, C 6-14 arylene, 5-to 10-membered heteroarylene, or 3-to 10-membered heterocyclylene, each of which is optionally substituted with one or more substituents Q.
  • each Z n is independently a bond, –C (O) –, –C (O) O–, –C (O) NR 1b –, –C (O) S–, –C (NR 1a ) NR 1b –, –C (S) –, –C (S) O–, –C (S) NR 1b –, –O–, –OC (O) O–, –OC (O) NR 1b –, –OC (O) S–, –OC (NR 1a ) NR 1b –, –OC (S) –, –OC (S) O–, –OC (S) NR 1b –, –OS (O) –, –OS (O) 2 –, –OS (O) NR 1b –, –OS (O) 2 NR 1b –, –NR 1b –, –NR 1a C (O) NR 1b –,
  • z is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • each R n is independently C 1-10 alkylene, C 2-10 alkynylene, C 3-10 cycloalkylene, C 6-14 arylene, 5-to 6-membered heteroarylene, or 5-to 6-membered heterocyclylene, each of which is optionally substituted with one or more substituents Q.
  • each R n is independently C 1-10 alkylene, or 5-to 6-membered heterocyclylene, each of which is optionally substituted with one or more substituents Q.
  • each R n is independently methanediyl, ethanediyl, propanediyl, butanediyl, pentanediyl, hexanediyl, heptanediyl, octanediyl, nonanediyl, decanediyl, undecanediyl, dodecanediyl, tridecanediyl, ethynediyl, propynediyl, pentynediyl, cyclobutanediyl, cyclopentanediyl, cyclohexanediyl, cycloheptanediyl, bicyclo [2.2.2] octanediyl, phendiyl, pyrazoldiyl, imidazoldiyl, tetrazoldiyl, pyr
  • each R n is independently methanediyl, cyclopropylmethanediyl, ethanediyl, pentanediyl, hexanediyl, heptanediyl, octanediyl, ethynediyl, propynediyl, pentynediyl, azetidindiyl, pyrrolidindiyl, piperazindiyl, or piperidindiyl.
  • each R n is independently methanediyl, cyclopropylmethanediyl, ethane-1, 2-diyl, pentane-1, 5-diyl, hexane-1, 6-diyl, heptane-1, 7-diyl, octane-1, 8-diyl, ethyne-1, 2-diyl, propyne-1, 3-diyl, 1-pentyne-1, 5-diyl, azetidin-1, 3-diyl, pyrrolidin-1, 3-diyl, piperazin-1, 4-diyl, or piperidin-1, 4-diyl.
  • each R n is independently methanediyl, piperazin-1, 4-diyl, or piperidin-1, 4-diyl.
  • each Z n is independently a bond, –C (O) –, –C (O) NR 1b –, –O–, –OC (O) NR 1b –, –NR 1b –, –NR 1a C (O) NR 1b –, or –S (O) 2 –.
  • each Z n is independently a bond, –C (O) –, –C (O) O–, –C (O) NH–, –OC (O) NH–, –O–, –NH–, –N (CH 3 ) –, –NHC (O) NH–, or –S (O) 2 –.
  • each Z n is independently a bond, –C (O) –, –C (O) NH–, –O–, –NH–, –N (CH 3 ) –, or –S (O) 2 –.
  • each Z n is independently a bond, or –C (O) –.
  • z is an integer of 1, 2, 3, 4, or 5.
  • z is an integer of 1, 2, or 3.
  • L is selected from the group consisting of the following:
  • L is selected from the group consisting of the following:
  • L is:
  • R is an E3 ubiquitin ligase binding moiety optionally substituted with one or more substituents Q.
  • R is a moiety of a cereblon (CRBN) E3 ligand, an inhibitors-of-apoptosis protein (IAP) E3 ligand, or a von Hippel-Lindau (VHL) E3 ligand.
  • CRBN cereblon
  • IAP inhibitors-of-apoptosis protein
  • VHL von Hippel-Lindau
  • R is a moiety of a cereblon (CRBN) E3 ligand.
  • R is a moiety having the structure of Formula (EC-I) : wherein, the variables are as defined in the context.
  • R e1 is hydrogen, deuterium, or halo. In certain embodiments, R e1 is C 1-6 alkyl. In certain embodiments, R e1 is C 1-6 haloalkyl. In certain embodiments, R e1 is C 2-6 alkenyl. In certain embodiments, R e1 is C 2-6 haloalkenyl. In certain embodiments, R e1 is C 2-6 alkynyl. In certain embodiments, R e1 is C 2-6 haloalkynyl. In certain embodiments, R e1 is optionally substituted with one or more substituents Q.
  • R e2 is hydrogen
  • each R e3 is independently (i) hydrogen, deuterium, cyano, halo, or nitro; (ii) C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, or C 2-6 haloalkynyl; (iii) C 1-6 heteroalkyl, C 2-6 heteroalkenyl, or C 2-6 heteroalkynyl; (iv) C 3-10 cycloalkyl, 3-to 10-membered heterocyclyl, C 6-14 aryl, C 7-15 aralkyl, 5-to 10-membered heteroaryl, or 6-to 11-membered heteroarylalkyl; or (v) –C (O) R 1a , –C (O) OR 1a , –C (O) NR 1b R 1c , –C (O) SR 1a , –C (NR 1a , –C
  • Z is –CH 2 –or –C (O) –.
  • n is an integer of 0, 1, or 2. In certain embodiments, m is an integer of 1, or 2.
  • n is an integer of 0, 1, 2, 3, or 4. In certain embodiments, n is an integer of 0, 1, 2, or 3. In certain embodiments, n is an integer of 1.
  • R is a moiety having the structure of Formula (EC-II) : wherein, the variables are as defined in the context.
  • R is a moiety having the structure of Formula (EC-III) : wherein, the variables are as defined in the context.
  • R is a moiety having the structure of Formula (EC-IV) : wherein, the variables are as defined in the context.
  • R is a moiety having the structure of:
  • R is a moiety having the structure of Formula (ED-I) : wherein, the variables are as defined in the context.
  • R e4 is hydrogen. In certain embodiments, R e4 is C 1-6 alkyl. In certain embodiments, R e4 is C 1-6 haloalkyl. In certain embodiments, R e4 is C 2-6 alkenyl. In certain embodiments, R e4 is C 2-6 haloalkenyl. In certain embodiments, R e4 is C 2-6 alkynyl. In certain embodiments, R e4 is C 2-6 haloalkynyl. In certain embodiments, R e4 is optionally substituted with one or more substituents Q.
  • R is a moiety having the structure of Formula (ED-II) : wherein, the variables are as defined in the context.
  • R is a moiety having the structure of Formula (ED-III) : wherein, the variables are as defined in the context.
  • R is a moiety having the structure of Formula (ED-IV) : wherein, the variables are as defined in the context.
  • R is a moiety having the structure of:
  • R is a moiety having the structure of Formula (EE-I) : wherein, the variables are as defined in the context.
  • R is a moiety having the structure of Formula (EE-II) : wherein, the variables are as defined in the context.
  • R is a moiety having the structure of Formula (EE-III) : wherein, the variables are as defined in the context.
  • R is a moiety having the structure of Formula (EE-IV) : wherein, the variables are as defined in the context.
  • R is a moiety having the structure of:
  • R is a moiety of a VHL E3 ligand.
  • R is a moiety having the structure of Formula (EV-I) : wherein, the variables are as defined in the context.
  • R v1 is hydrogen. In certain embodiments, R v1 is deuterium. In certain embodiments, R v1 is C 1-6 alkyl. In certain embodiments, R v1 is C 3-10 cycloalkyl. In certain embodiments, R v1 is methyl. In certain embodiments, R v1 is each optionally substituted with one or more substituents Q.
  • R v2 is hydrogen. In certain embodiments, R v2 is deuterium. In certain embodiments, R v2 is halo. In certain embodiments, R v2 is hydroxyl. In certain embodiments, R v2 is –OC 1-6 alkyl. In certain embodiments, R v2 is –OC 3-10 cycloalkyl. In certain embodiments, R v2 is optionally substituted with one or more substituents Q.
  • R v3 is hydrogen. In certain embodiments, R v3 is deuterium. In certain embodiments, R v3 is C 1-6 alkyl. In certain embodiments, R v3 is C 3-10 cycloalkyl. In certain embodiments, R v3 is each optionally substituted with one or more substituents Q.
  • R v4 is hydrogen. In certain embodiments, R v4 is deuterium. In certain embodiments, R v4 is C 1-6 alkyl. In certain embodiments, R v4 is C 3-10 cycloalkyl. In certain embodiments, R v4 is propyl, butyl, or cyclopropyl. In certain embodiments, R v4 is isopropyl, tert-butyl, cyclopropyl, 1-fluorocyclopropyl, or 1-trifuloromethylcyclopropyl. In certain embodiments, R v4 is each optionally substituted with one or more substituents Q.
  • R is a moiety having the structure of:
  • any technical solution in any one of the above specific embodiments, or any combination thereof may be combined with any technical solution in other specific embodiments or any combination thereof.
  • any technical solution of R 1 or any combination thereof may be combined with any technical solution of R 2 , R 3 , R 4 , R 5a , R 5b , R 5a1 , R 5b1 , R 6 , R 6a , E, W, A, L, R, m, n, b or any combination thereof.
  • the present disclosure is intended to include all combination of such technical solutions, which are not exhaustively listed here to save space.
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein, R 1 is (i) hydrogen, deuterium, or halo; (ii) C1-6 alkyl, or C1-6 haloalkyl; or (iii) 5-to 6-membered heteroaryl, which is optionally substituted with NH 2 .
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein, is a double bond.
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein, R 1 is (i) hydrogen, deuterium, or halo; or (ii) C 1-6 alkyl, or C 1-6 haloalkyl; alternatively R 1 is (i) hydrogen, or deuterium.
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein, R 2 is (iii) 5-to 6-membered heteroaryl (e.g., 6-membered heteroaryl, such as pyridyl) , which is optionally substituted with OH, or NH 2 .
  • 5-to 6-membered heteroaryl e.g., 6-membered heteroaryl, such as pyridyl
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein R 3 is (i) hydrogen, deuterium, or halogen.
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein R 4 is (i) hydrogen; or (ii) C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, or C 2-6 haloalkynyl; alternatively R 4 is (i) hydrogen.
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein R 5a , R 5b , R 5a1 and R 5b1 are each independently (i) hydrogen, deuterium, or cyano; or (ii) C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, or C 2-6 haloalkynyl; alternatively R 5a , R 5b , R 5a1 and R 5b1 are each independently (i) hydrogen, or deuterium; or (ii) C 1-6 alkyl, or
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein E is O, or S; alternatively E is O.
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein W is CR 6’ , and R 6’ is (i) hydrogen, deuterium, or halo; or (ii) C 1-6 haloalkyl, C 2-6 haloalkenyl, or C 2-6 haloalkynyl.
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein R 6 is (i) hydrogen, deuterium, cyano, halo, or nitro; or (ii) C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, or C 2-6 haloalkynyl; alternatively R 6 is (i) hydrogen, deuterium, or halo; or (ii) C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, wherein R 6
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein A is C 3-10 cycloalkylene, or C 6-14 arylene, each optionally substituted with one or more substituents Q; alternatively A is C 5-6 cycloalkylene, or C 6-10 arylene, each optionally substituted with one or more substituents Q; alternatively A is C 6 cycloalkylene such as cyclohexadiyl or cyclohexendiyl, or phendiyl such as phen-1, 4-diyl, each optionally substituted with one or more substituents Q.
  • A is C 3-10 cycloalkylene
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein L has the structure of:–Z n – (R n –Z n ) z –;wherein:each R n is independently C 1-20 alkylene, C 2-20 alkenylene, C 2-20 alkynylene, C 3-10 cycloalkylene, C 6-14 arylene, 5-to 10-membered heteroarylene, or 3-to 10-membered heterocyclylene, each of which is optionally substituted with one or more substituents Q;each Z n is independently a bond, –C (O) –, –C (O) O–
  • L is:
  • the present disclosure provides a compound of formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein R is a moiety of a cereblon (CRBN) E3 ligand, an inhibitors-of-apoptosis protein (IAP) E3 ligand, or a von Hippel-Lindau (VHL) E3 ligand;
  • CRBN cereblon
  • IAP inhibitors-of-apoptosis protein
  • VHL von Hippel-Lindau
  • R is a moiety of a cereblon (CRBN) E3 ligand
  • R is a moiety having the structure of Formula (EC-I) : wherein:R e1 is (i) hydrogen, deuterium, or halo; or (ii) C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, or C 2-6 haloalkynyl, optionally substituted with one or more substituents Q;R e2 is hydrogen;each R e3 is independently (i) hydrogen, deuterium, cyano, halo, or nitro; (ii) C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 haloalkenyl, C 2-6 alkynyl, or C 2-6 haloalkynyl; (iii) C 1-6 heteroalkyl, C 2-6 heteroalkenyl, or C 2-6 heteroalkynyl; (iv) C 1-6
  • a compound of Formula (II) , (III) , (III') , (IV) , (IV’) , (V) , (V’) , (VI) or (VI’) wherein, are each a single bond or double bond;
  • X is N, CR 7a , NH, or CHR 7a
  • Y is N, CR 7e , NH, or CHR 7e ,R 7a , R 7b , R 7d , and R 7e are each independently (i) hydrogen, deuterium, cyano, halo, or nitro;
  • a compound of formula (III) , (III’ ) or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof: wherein, is a single bond or a double bond; is a single bond or a double bond; is a single bond or a double bond; is a single bond or a double bond; is a single bond or a double bond;R 1 is (i) hydrogen, deuterium, or halo; or (ii) C 1-6 alkyl, or C 1-6 haloalkyl;R 2 is 5-to 6-membered heteroaryl, which is optionally substituted with OH, or NH 2 ;R 3 is (i) hydrogen, deuterium, or halo; or (ii) C 1-6
  • G is H, F, OH.
  • a compound of formula (V) or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof,wherein, is a single bond or a double bond; is a single bond or a double bond; is a single bond or a double bond; is a single bond or a double bond;R 2 is R 5a , R 5b , R 5a1 and R 5b1 are each independently (i) hydrogen, or deuterium;R 6 is (i) hydrogen, deuterium, or halo; or (ii) C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, or C 2-6 alkynyl;W is N or CR 6’ ; wherein R 6’ is (i) hydrogen
  • a compound of formula (V) or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is a single bond or a double bond; is a single bond or a double bond; is a single bond or a double bond;R 2 is R 5a , R 5b , R 5a1 and R 5b1 are each independently (i) hydrogen, or deuterium; or (ii) C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, or C 2-6 alkynyl;R 6 is (i) hydrogen, deuterium, or halo; or (ii) C 1-6 alkyl, C 1-6 haloalkyl, C 2
  • a compound provided herein is deuterium-enriched. In certain embodiments, a compound provided herein is carbon-13 enriched. In certain embodiments, a compound provided herein is carbon-14 enriched. In certain embodiments, a compound provided herein contains one or more less prevalent isotopes for other elements, including, but not limited to, 15 N for nitrogen; 17 O or 18 O for oxygen, and 34 S, 35 S, or 36 S for sulfur.
  • a compound provided herein has an isotopic enrichment factor of no less than about 5, no less than about 10, no less than about 20, no less than about 50, no less than about 100, no less than about 200, no less than about 500, no less than about 1,000, no less than about 2,000, no less than about 5,000, or no less than about 10,000.
  • an isotopic enrichment factor for a specified isotope is no greater than the maximum isotopic enrichment factor for the specified isotope, which is the isotopic enrichment factor when a compound at a given position is 100%enriched with the specified isotope.
  • the maximum isotopic enrichment factor is different for different isotopes.
  • the maximum isotopic enrichment factor is 6, 410 for deuterium and 90 for carbon-13.
  • a compound provided herein has a deuterium enrichment factor of no less than about 64 (about 1%deuterium enrichment) , no less than about 130 (about 2%deuterium enrichment) , no less than about 320 (about 5%deuterium enrichment) , no less than about 640 (about 10%deuterium enrichment) , no less than about 1, 300 (about 20%deuterium enrichment) , no less than about 3, 200 (about 50%deuterium enrichment) , no less than about 4, 800 (about 75%deuterium enrichment) , no less than about 5, 130 (about 80%deuterium enrichment) , no less than about 5, 450 (about 85%deuterium enrichment) , no less than about 5, 770 (about 90%deuterium enrichment) , no less than about 6, 090 (about 95%deuterium enrichment) , no less than about 6, 220 (about 97%deuterium enrichment) , no less than about 6, 280 (about 98%deuterium enrichment) , no
  • the deuterium enrichment can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.
  • at least one of the atoms of a compound provided herein, as specified as deuterium-enriched has deuterium enrichment of no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%.
  • a compound provided herein is isolated or purified. In certain embodiments, a compound provided herein has a purity of at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 99.5%by weight.
  • the compounds provided herein are intended to encompass all possible stereoisomers unless a particular stereochemistry is specified.
  • a compound provided herein contains an alkenyl group
  • the compound may exist as one or mixture of geometric cis/trans (or Z/E) isomers.
  • structural isomers are interconvertible
  • the compound may exist as a single tautomer or a mixture of tautomers. This can take the form of proton tautomerism in the compound that contains, for example, an imino, keto, or oxime group; or so-called valence tautomerism in the compound that contains an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.
  • a compound provided herein can be enantiomerically pure, such as a single enantiomer or a single diastereomer, or be stereoisomeric mixtures, such as a mixture of enantiomers, e.g., a racemic mixture of two enantiomers; or a mixture of two or more diastereomers.
  • a compound in its (R) form is equivalent, for the compound that undergoes epimerization in vivo, to administration of the compound in its (S) form.
  • Conventional techniques for the preparation/isolation of individual enantiomers include synthesis from a suitable optically pure precursor, asymmetric synthesis from achiral starting materials, or resolution of an enantiomeric mixture, for example, chiral chromatography, recrystallization, resolution, diastereomeric salt formation, or derivatization into diastereomeric adducts followed by separation.
  • a pharmaceutically acceptable salt of a compound provided herein is a solvate.
  • a pharmaceutically acceptable salt of a compound provided herein is a hydrate.
  • Suitable acids for use in the preparation of pharmaceutically acceptable salts of a compound provided herein include, but are not limited to, acetic acid, 2, 2-dichloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, boric acid, (+) -camphoric acid, camphorsulfonic acid, (+) - (1S) -camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, cyclohexanesulfamic acid, dodecylsulfuric acid, ethane-1, 2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid
  • Suitable bases for use in the preparation of pharmaceutically acceptable salts of a compound provided herein include, but are not limited to, inorganic bases, such as magnesium hydroxide, calcium hydroxide, potassium hydroxide, zinc hydroxide, and sodium hydroxide; and organic bases, such as primary, secondary, tertiary, and quaternary, aliphatic and aromatic amines, including, but not limited to, L-arginine, benethamine, benzathine, choline, deanol, diethanolamine, diethylamine, dimethylamine, dipropylamine, diisopropylamine, 2- (diethylamino) -ethanol, ethanolamine, ethylamine, ethylenediamine, isopropylamine, N-methyl-glucamine, hydrabamine, 1H-imidazole, L-lysine, morpholine, 4- (2-hydroxyethyl) -morpholine, methylamine, piperidine, piperazine, propy
  • a compound provided herein may also be provided as a prodrug, which is a functional derivative of the compound and is readily convertible into the parent compound in vivo.
  • Prodrugs are often useful because, in some situations, they may be easier to administer than the parent compound. They may, for instance, be bioavailable by oral administration whereas the parent compound is not.
  • the prodrug may also have enhanced solubility in pharmaceutical compositions over the parent compound.
  • a prodrug may be converted into the parent drug by various mechanisms, including enzymatic processes and metabolic hydrolysis.Pharmaceutical Compositions
  • a pharmaceutical composition comprising a compound provided herein, e.g., a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient.
  • a compound provided herein e.g., a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient.
  • the pharmaceutical composition provided herein can be formulated in various dosage forms, including, but not limited to, dosage forms for oral, parenteral, and topical administration.
  • the pharmaceutical composition can also be formulated as modified release dosage forms, including delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated-, fast-, targeted-, programmed-release, and gastric retention dosage forms.
  • These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art. See, e.g., Remington: The Science and Practice of Pharmacy, supra; Modified-Release Drug Delivery Technology, 2nd ed.; Rathbone et al., Eds.; Drugs and the Pharmaceutical Sciences 184; CRC Press: Boca Raton, FL, 2008.
  • the pharmaceutical composition provided herein is formulated in a dosage form for oral administration. In another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for parenteral administration. In yet another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for intravenous administration. In yet another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for intramuscular administration. In yet another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for subcutaneous administration. In still another embodiment, the pharmaceutical composition provided herein is formulated in a dosage form for topical administration.
  • the pharmaceutical composition provided herein can be provided in a unit-dosage form or multiple-dosage form.
  • a unit-dosage form refers to physically discrete a unit suitable for administration to a subject, and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of an active ingredient (s) (e.g., a compound provided herein) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical excipient (s) .
  • an active ingredient e.g., a compound provided herein
  • Examples of a unit-dosage form include, but are not limited to, an ampoule, syringe, and individually packaged tablet and capsule.
  • a unit-dosage form may be administered in fractions or multiples thereof.
  • a multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in a segregated unit-dosage form.
  • Examples of a multiple-dosage form include, are not limited to, a vial, bottle of tablets or capsules, or bottle of pints or gallons.
  • the pharmaceutical composition provided herein can be administered at once or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the subject being treated, and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the subject’s need and the professional judgment of the person administering or supervising the administration of the pharmaceutical composition.A. Oral Administration
  • oral administration can be provided in solid, semisolid, or liquid dosage forms for oral administration.
  • oral administration also includes buccal, lingual, and sublingual administration.
  • Suitable oral dosage forms include, but are not limited to, tablets, fastmelts, chewable tablets, capsules, pills, strips, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, oral mists, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups.
  • the pharmaceutical composition can contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, flavoring agents, emulsifying agents, suspending and dispersing agents, preservatives, solvents, non-aqueous liquids, organic acids, and sources of carbon dioxide.
  • pharmaceutically acceptable carriers or excipients including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, flavoring agents, emulsifying agents, suspending and dispersing agents, preservatives, solvents, non-aqueous liquids, organic acids, and sources of carbon dioxide.
  • Binders or granulators impart cohesiveness to a tablet to ensure the tablet remaining intact after compression.
  • Suitable binders or granulators include, but are not limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (e.g., STARCH ) ; gelatin; sugars, such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss, Panwar gum, Ghatti gum, mucilage of isabgol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP) , larch arabinogalactan, powdered tragacanth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethy
  • Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, and pre-gelatinized starch.
  • the amount of a binder or filler in the pharmaceutical composition provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
  • the binder or filler may be present from about 50 to about 99%by weight in the pharmaceutical composition provided herein.
  • Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar.
  • Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such compressed tablets can be used as chewable tablets.
  • the amount of a diluent in the pharmaceutical composition provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
  • Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation-exchange resins; alginic acid; gums, such as guar gum and HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrilin potassium; starches, such as corn starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; and algins.
  • the amount of a disintegrant in the pharmaceutical composition provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
  • the pharmaceutical composition provided herein may contain from about 0.5 to about 15%or from about 1 to about 5%by weight of a disintegrant.
  • Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glycerol behenate and polyethylene glycol (PEG) ; stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oil, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch; lycopodium; and silica or silica gels, such as 200 and
  • the amount of a lubricant in the pharmaceutical composition provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art.
  • the pharmaceutical compositions provided herein may contain about 0.1 to about 5%by weight of a lubricant.
  • Suitable glidants include, but are not limited to, colloidal silicon dioxide, and asbestos-free talc.
  • Suitable coloring agents include, but are not limited to, any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes.
  • a color lake is a combination by absorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye.
  • Suitable flavoring agents include, but are not limited to, natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate.
  • Suitable sweetening agents include, but are not limited to, sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame.
  • Suitable emulsifying agents include, but are not limited to, gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate polyoxyethylene sorbitan monooleate 80 and triethanolamine oleate.
  • Suitable suspending and dispersing agents include, but are not limited to, sodium carboxymethylcellulose, pectin, tragacanth, acacia, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone.
  • Suitable preservatives include, but are not limited to, glycerin, methyl and propylparaben, benzoic add, and sodium benzoate and alcohol.
  • Suitable wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether.
  • Suitable solvents include, but are not limited to, glycerin, sorbitol, ethyl alcohol, and syrup.
  • Suitable non-aqueous liquids utilized in emulsions include, but are not limited to, mineral oil and cottonseed oil.
  • Suitable organic acids include, but are not limited to, citric and tartaric acid.
  • Suitable sources of carbon dioxide include, but are not limited to, sodium bicarbonate and sodium carbonate.
  • the pharmaceutical composition provided herein for oral administration can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets.
  • Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredient (s) from the acidic environment of the stomach.
  • Enteric-coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates.
  • Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation.
  • Film-coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material.
  • Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coating imparts the same general characteristics as sugar coating.
  • Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press-coated or dry-coated tablets.
  • the tablet dosage forms can be prepared from an active ingredient (s) in powdered, crystalline, or granular forms, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled-release polymers, lubricants, diluents, and/or colorants. Flavoring and sweetening agents are especially useful in the formation of chewable tablets and lozenges.
  • the pharmaceutical composition provided herein for oral administration can be provided as soft or hard capsules, which can be made from gelatin, methylcellulose, starch, or calcium alginate.
  • the hard gelatin capsule also known as the dry-filled capsule (DFC) , consists of two sections, one slipping over the other, thus completely enclosing the active ingredient (s) .
  • the soft elastic capsule (SEC) is a soft, globular shell, such as a gelatin shell, which is plasticized by the addition of glycerin, sorbitol, or a similar polyol.
  • the soft gelatin shells may contain a preservative to prevent the growth of microorganisms.
  • Suitable preservatives are those as described herein, including methyl-and propyl-parabens, and sorbic acid.
  • the liquid, semisolid, and solid dosage forms provided herein may be encapsulated in a capsule.
  • Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils, or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545.
  • the capsules may also be coated as known by those of skill in the art in order to modify or sustain dissolution of the active ingredient (s) .
  • the pharmaceutical composition provided herein for oral administration can be provided in liquid and semisolid dosage forms, including emulsions, solutions, suspensions, elixirs, and syrups.
  • An emulsion is a two-phase system, in which one liquid is dispersed in the form of small globules throughout another liquid, which can be oil-in-water or water-in-oil.
  • Emulsions may include a pharmaceutically acceptable non-aqueous liquid or solvent, emulsifying agent, and preservative.
  • Suspensions may include a pharmaceutically acceptable suspending agent and preservative.
  • Aqueous alcoholic solutions may include a pharmaceutically acceptable acetal, such as a di(lower alkyl) acetal of a lower alkyl aldehyde, e.g., acetaldehyde diethyl acetal; and a water-miscible solvent having one or more hydroxyl groups, such as propylene glycol and ethanol.
  • Elixirs are clear, sweetened, and hydroalcoholic solutions.
  • Syrups are concentrated aqueous solutions of a sugar, for example, sucrose, and may also contain a preservative.
  • a solution in a polyethylene glycol may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g., water, to be measured conveniently for administration.
  • liquid and semisolid dosage forms include, but are not limited to, those containing an active ingredient (s) , and a dialkylated mono-or poly-alkylene glycol, including, 1, 2-dimethoxymethane, diglyme, triglyme, tetraglyme, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether, wherein 350, 550, and 750 refer to the approximate average molecular weight of the polyethylene glycol.
  • a dialkylated mono-or poly-alkylene glycol including, 1, 2-dimethoxymethane, diglyme, triglyme, tetraglyme, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether, wherein 350, 550, and 750 refer to the approximate average molecular weight of the polyethylene glycol.
  • These dosage forms can further comprise one or more antioxidants, such as butylated hydroxytoluene (BHT) , butylated hydroxyanisole (BHA) , propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, bisulfite, sodium metabisulfite, thiodipropionic acid and its esters, and dithiocarbamates.
  • antioxidants such as butylated hydroxytoluene (BHT) , butylated hydroxyanisole (BHA) , propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, bisulfite, sodium metabisulfite, thiodipropionic acid and its esters, and dithiocarba
  • composition provided herein for oral administration can also be provided in the forms of liposomes, micelles, microspheres, or nanosystems.
  • Micellar dosage forms can be prepared as described in U.S. Pat. No. 6,350,458.
  • the pharmaceutical composition provided herein for oral administration can be provided as non-effervescent or effervescent, granules and powders, to be reconstituted into a liquid dosage form.
  • Pharmaceutically acceptable carriers and excipients used in the non-effervescent granules or powders may include diluents, sweeteners, and wetting agents.
  • Pharmaceutically acceptable carriers and excipients used in the effervescent granules or powders may include organic acids and a source of carbon dioxide.
  • Coloring and flavoring agents can be used in all of the dosage forms described herein.
  • compositions provided herein for oral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.B. Parenteral Administration
  • compositions provided herein can be administered parenterally by injection, infusion, or implantation, for local or systemic administration.
  • Parenteral administration includes intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial, intravesical, and subcutaneous administration.
  • the pharmaceutical composition provided herein for parenteral administration can be formulated in any dosage forms that are suitable for parenteral administration, including, but not limited to, solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid prior to injection.
  • dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science. See, e.g., Remington: The Science and Practice of Pharmacy, supra.
  • the pharmaceutical composition provided herein for parenteral administration can include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting agents, and inert gases.
  • aqueous vehicles water-miscible vehicles
  • non-aqueous vehicles non-aqueous vehicles
  • antimicrobial agents or preservatives against the growth of microorganisms stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or
  • Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS) , sodium chloride injection, Ringer’s injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringer’s injection.
  • Suitable non-aqueous vehicles include, but are not limited to, fixed oils of vegetable origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, hydrogenated soybean oil, and medium-chain triglycerides of coconut oil, and palm seed oil.
  • Suitable water-miscible vehicles include, but are not limited to, ethanol, 1, 3-butanediol, liquid polyethylene glycol (e.g., polyethylene glycol 300 and polyethylene glycol 400) , propylene glycol, glycerin, N-methyl-2-pyrrolidone, N, N-dimethylacetamide, and dimethyl sulfoxide.
  • liquid polyethylene glycol e.g., polyethylene glycol 300 and polyethylene glycol 400
  • propylene glycol e.g., propylene glycol, glycerin, N-methyl-2-pyrrolidone, N, N-dimethylacetamide, and dimethyl sulfoxide.
  • Suitable antimicrobial agents or preservatives include, but are not limited to, phenols, cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoates, thimerosal, benzalkonium chloride (e.g., benzethonium chloride) , methyl-and propyl-parabens, and sorbic acid.
  • Suitable isotonic agents include, but are not limited to, sodium chloride, glycerin, and dextrose.
  • Suitable buffering agents include, but are not limited to, phosphate and citrate.
  • Suitable antioxidants include those described herein, such as bisulfite and sodium metabisulfite.
  • Suitable local anesthetics include, but are not limited to, procaine hydrochloride.
  • Suitable suspending and dispersing agents include those described herein, such as sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone.
  • Suitable emulsifying agents include those described herein, such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate.
  • Suitable sequestering or chelating agents include, but are not limited to, EDTA.
  • Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid.
  • Suitable complexing agents include, but are not limited to, cyclodextrins, including ⁇ -cyclodextrin, ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, sulfobutylether- ⁇ -cyclodextrin, and sulfobutylether 7- ⁇ -cyclodextrin
  • multiple dosage parenteral formulations must contain an antimicrobial agent at bacteriostatic or fungistatic concentrations. All parenteral formulations must be sterile, as known and practiced in the art.
  • the pharmaceutical composition for parenteral administration is provided as a ready-to-use sterile solution.
  • the pharmaceutical composition is provided as a sterile dry soluble product, including a lyophilized powder and hypodermic tablet, to be reconstituted with a vehicle prior to use.
  • the pharmaceutical composition is provided as a ready-to-use sterile suspension.
  • the pharmaceutical composition is provided as a sterile dry insoluble product to be reconstituted with a vehicle prior to use.
  • the pharmaceutical composition is provided as a ready-to-use sterile emulsion.
  • compositions provided herein for parenteral administration can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.
  • the pharmaceutical composition provided herein for parenteral administration can be formulated as a suspension, solid, semi-solid, or thixotropic liquid, for administration as an implanted depot.
  • the pharmaceutical composition provided herein are dispersed in a solid inner matrix, which is surrounded by an outer polymeric membrane that is insoluble in body fluids but allows the active ingredient (s) in the pharmaceutical composition to diffuse through.
  • Suitable inner matrixes include, but are not limited to, polymethylmethacrylate, polybutylmethacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers (such as hydrogels of esters of acrylic and methacrylic acid) , collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.
  • Suitable outer polymeric membranes include, but are not limited to, polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinyl acetate copolymers, silicone rubbers, polydimethylsiloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer.C. Topical Administration
  • the pharmaceutical composition provided herein can be administered topically to the skin, orifices, or mucosa.
  • the topical administration includes (intra) dermal, conjunctival, intracorneal, intraocular, ophthalmic, auricular, transdermal, nasal, vaginal, urethral, respiratory, and rectal administration.
  • the pharmaceutical composition provided herein can be formulated in any dosage forms that are suitable for topical administration for local or systemic effect, including, but not limited to, emulsions, solutions, suspensions, creams, gels, hydrogels, ointments, dusting powders, dressings, elixirs, lotions, suspensions, tinctures, pastes, foams, films, aerosols, irrigations, sprays, suppositories, bandages, and dermal patches.
  • the topical formulations of the pharmaceutical composition provided herein can also comprise liposomes, micelles, microspheres, and nanosystems.
  • Pharmaceutically acceptable carriers and excipients suitable for use in the topical formulations include, but are not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, penetration enhancers, cryoprotectants, lyoprotectants, thickening agents, and inert gases.
  • the pharmaceutical composition can also be administered topically by electroporation, iontophoresis, phonophoresis, sonophoresis, or microneedle or needle-free injection, such as POWDERJECTTM and BIOJECTTM.
  • Suitable ointment vehicles include oleaginous or hydrocarbon vehicles, including lard, benzoinated lard, olive oil, cottonseed oil, and other oils, white petrolatum; emulsifiable or absorption vehicles, such as hydrophilic petrolatum, hydroxystearin sulfate, and anhydrous lanolin; water-removable vehicles, such as hydrophilic ointment; water-soluble ointment vehicles, including polyethylene glycols of varying molecular weight; emulsion vehicles, either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, including cetyl alcohol, glyceryl monostearate, lanolin, and stearic acid. See, e.g., Remington: The Science and Practice of Pharmacy, supra. These vehicles are emollient but generally require
  • Suitable cream base can be oil-in-water or water-in-oil.
  • Suitable cream vehicles may be water-washable, and contain an oil phase, an emulsifier, and an aqueous phase.
  • the oil phase is also called the “internal” phase, which is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol.
  • the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant.
  • the emulsifier in a cream formulation may be a nonionic, anionic, cationic, or amphoteric surfactant.
  • Gels are semisolid, suspension-type systems. Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the liquid carrier.
  • Suitable gelling agents include, but are not limited to, crosslinked acrylic acid polymers, such as carbomers, carboxypolyalkylenes, and hydrophilic polymers, such as polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers, and polyvinylalcohol; cellulosic polymers, such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and methylcellulose; gums, such as tragacanth and xanthan gum; sodium alginate; and gelatin.
  • dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing, and/or stirring.
  • the pharmaceutical composition provided herein can be administered rectally, urethrally, vaginally, or perivaginally in the forms of suppositories, pessaries, bougies, poultices or cataplasm, pastes, powders, dressings, creams, plasters, contraceptives, ointments, solutions, emulsions, suspensions, tampons, gels, foams, sprays, or enemas.
  • These dosage forms can be manufactured using conventional processes as described in Remington: The Science and Practice of Pharmacy, supra.
  • Rectal, urethral, and vaginal suppositories are solid bodies for insertion into body orifices, which are solid at ordinary temperatures but melt or soften at body temperature to release the active ingredient (s) inside the orifices.
  • Pharmaceutically acceptable carriers utilized in rectal and vaginal suppositories include bases or vehicles, such as stiffening agents, which produce a melting point in the proximity of body temperature, when formulated with an active ingredient (s) ; and antioxidants as described herein, including bisulfite and sodium metabisulfite.
  • Suitable vehicles include, but are not limited to, cocoa butter (theobroma oil) , glycerin-gelatin, carbowax (polyoxyethylene glycol) , spermaceti, paraffin, white and yellow wax, and appropriate mixtures of mono-, di-and triglycerides of fatty acids, and hydrogels, such as polyvinyl alcohol, hydroxyethyl methacrylate, and polyacrylic acid. Combinations of the various vehicles can also be used. Rectal and vaginal suppositories may be prepared by compressing or molding. The typical weight of a rectal and vaginal suppository is about 2 to about 3 g.
  • compositions provided herein can be administered ophthalmically in the forms of solutions, suspensions, ointments, emulsions, gel-forming solutions, powders for solutions, gels, ocular inserts, and implants.
  • the pharmaceutical composition provided herein can be administered intranasally or by inhalation to the respiratory tract.
  • the pharmaceutical composition can be provided in the form of an aerosol or solution for delivery using a pressurized container, pump, spray, atomizer, such as an atomizer using electrohydrodynamics to produce a fine mist, or nebulizer, alone or in combination with a suitable propellant, such as 1, 1, 1, 2-tetrafluoroethane or 1, 1, 1, 2, 3, 3, 3-heptafluoropropane.
  • atomizer such as an atomizer using electrohydrodynamics to produce a fine mist, or nebulizer, alone or in combination with a suitable propellant, such as 1, 1, 1, 2-tetrafluoroethane or 1, 1, 1, 2, 3, 3, 3-heptafluoropropane.
  • the pharmaceutical composition can also be provided as a dry powder for insufflation, alone or in combination with an inert carrier such as lactose or phospholipids; and nasal drops.
  • Solutions or suspensions for use in a pressurized container, pump, spray, atomizer, or nebulizer can be formulated to contain ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilizing, or extending release of an active ingredient (s) ; a propellant as solvent; and/or a surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
  • the pharmaceutical composition provided herein can be micronized to a size suitable for delivery by inhalation, such as about 50 micrometers or less, or about 10 micrometers or less.
  • Particles of such sizes can be prepared using a comminuting method known to those skilled in the art, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying.
  • Capsules, blisters, and cartridges for use in an inhaler or insufflator can be formulated to contain a powder mix of the pharmaceutical composition provided herein; a suitable powder base, such as lactose or starch; and a performance modifier, such as l-leucine, mannitol, or magnesium stearate.
  • the lactose may be anhydrous or in the form of the monohydrate.
  • Other suitable excipients or carriers include, but are not limited to, dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, and trehalose.
  • the pharmaceutical composition provided herein for inhaled/intranasal administration can further comprise a suitable flavor, such as menthol and levomenthol; and/or sweeteners, such as saccharin and saccharin sodium.
  • compositions provided herein for topical administration can be formulated to be immediate release or modified release, including delayed-, sustained-, pulsed-, controlled-, targeted, and programmed release.D. Modified Release
  • modified release refers to a dosage form in which the rate or place of release of an active ingredient (s) is different from that of an immediate dosage form when administered by the same route.
  • Modified release dosage forms include, but are not limited to, delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated-and fast-, targeted-, programmed-release, and gastric retention dosage forms.
  • the pharmaceutical composition in modified release dosage forms can be prepared using a variety of modified release devices and methods known to those skilled in the art, including, but not limited to, matrix-controlled release devices, osmotic controlled release devices, multiparticulate controlled release devices, ion-exchange resins, enteric coatings, multilayered coatings, microspheres, liposomes, and combinations thereof.
  • the release rate of the active ingredient (s) can also be modified by varying the particle sizes and polymorphism of the active ingredient (s) .1.
  • Matrix Controlled Release Devices can also be modified by varying the particle sizes and polymorphism of the active ingredient (s) .1.
  • the pharmaceutical composition provided herein in a modified release dosage form can be fabricated using a matrix-controlled release device known to those skilled in the art. See, e.g., Takada et al. in Encyclopedia of Controlled Drug Delivery, Mathiowitz Ed.; Wiley, 1999; Vol. 2.
  • the pharmaceutical composition provided herein in a modified release dosage form is formulated using an erodible matrix device, which is water-swellable, erodible, or soluble polymers, including, but not limited to, synthetic polymers, and naturally occurring polymers and derivatives, such as polysaccharides and proteins.
  • an erodible matrix device which is water-swellable, erodible, or soluble polymers, including, but not limited to, synthetic polymers, and naturally occurring polymers and derivatives, such as polysaccharides and proteins.
  • Materials useful in forming an erodible matrix include, but are not limited to, chitin, chitosan, dextran, and pullulan; gum agar, gum arabic, gum karaya, locust bean gum, gum tragacanth, carrageenans, gum Ghatti, guar gum, xanthan gum, and scleroglucan; starches, such as dextrin and maltodextrin; hydrophilic colloids, such as pectin; phosphatides, such as lecithin; alginates; propylene glycol alginate; gelatin; collagen; cellulosics, such as ethyl cellulose (EC) , methylethyl cellulose (MEC) , carboxymethyl cellulose (CMC) , CMEC, hydroxyethyl cellulose (HEC) , hydroxypropyl cellulose (HPC) , cellulose acetate (CA) , cellulose propionate (CP) ,
  • the pharmaceutical composition provided herein is formulated with a non-erodible matrix device.
  • the active ingredient (s) is dissolved or dispersed in an inert matrix and is released primarily by diffusion through the inert matrix once administered.
  • Materials suitable for use as a non-erodible matrix device include, but are not limited to, insoluble plastics, such as polyethylene, polypropylene, polyisoprene, polyisobutylene, polybutadiene, polymethylmethacrylate, polybutylmethacrylate, chlorinated polyethylene, polyvinylchloride, methyl acrylate-methyl methacrylate copolymers, ethylene-vinyl acetate copolymers, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubbers, epichlorohydrin
  • the desired release kinetics can be controlled, for example, via the polymer type employed, the polymer viscosity, the particle sizes of the polymer and/or the active ingredient (s) , the ratio of the active ingredient (s) versus the polymer, and other excipients or carriers in the compositions.
  • composition provided herein in a modified release dosage form can be prepared by methods known to those skilled in the art, including direct compression, dry or wet granulation followed by compression, and melt-granulation followed by compression.2.
  • Osmotic Controlled Release Devices including direct compression, dry or wet granulation followed by compression, and melt-granulation followed by compression.2.
  • the pharmaceutical composition provided herein in a modified release dosage form can be fabricated using an osmotic controlled release device, including, but not limited to, one-chamber system, two-chamber system, asymmetric membrane technology (AMT) , and extruding core system (ECS) .
  • an osmotic controlled release device including, but not limited to, one-chamber system, two-chamber system, asymmetric membrane technology (AMT) , and extruding core system (ECS) .
  • AMT asymmetric membrane technology
  • ECS extruding core system
  • such devices have at least two components: (a) a core which contains an active ingredient; and (b) a semipermeable membrane with at least one delivery port, which encapsulates the core.
  • the semipermeable membrane controls the influx of water to the core from an aqueous environment of use so as to cause drug release by extrusion through the delivery port (s) .
  • the core of the osmotic device optionally includes an osmotic agent, which creates a driving force for transport of water from the environment of use into the core of the device.
  • an osmotic agent is water-swellable hydrophilic polymers, which are also referred to as “osmopolymers” and “hydrogels.
  • Suitable water-swellable hydrophilic polymers as osmotic agents include, but are not limited to, hydrophilic vinyl and acrylic polymers, polysaccharides such as calcium alginate, polyethylene oxide (PEO) , polyethylene glycol (PEG) , polypropylene glycol (PPG) , poly (2-hydroxyethyl methacrylate) , poly (acrylic) acid, poly (methacrylic) acid, polyvinylpyrrolidone (PVP) , crosslinked PVP, polyvinyl alcohol (PVA) , PVA/PVP copolymers, PVA/PVP copolymers with hydrophobic monomers such as methyl methacrylate and vinyl acetate, hydrophilic polyurethanes containing large PEO blocks, sodium croscarmellose, carrageenan, hydroxyethyl cellulose (HEC) , hydroxypropyl cellulose (HPC) , hydroxypropyl methyl cellulose (HPMC) , carboxymethyl me
  • osmogens which are capable of imbibing water to affect an osmotic pressure gradient across the barrier of the surrounding coating.
  • Suitable osmogens include, but are not limited to, inorganic salts, such as magnesium sulfate, magnesium chloride, calcium chloride, sodium chloride, lithium chloride, potassium sulfate, potassium phosphates, sodium carbonate, sodium sulfite, lithium sulfate, potassium chloride, and sodium sulfate; sugars, such as dextrose, fructose, glucose, inositol, lactose, maltose, mannitol, raffinose, sorbitol, sucrose, trehalose, and xylitol; organic acids, such as ascorbic acid, benzoic acid, fumaric acid, citric acid, maleic acid, sebacic acid, sorbic acid, adipic acid, edetic acid, gluta
  • Osmotic agents of different dissolution rates can be employed to influence how rapidly the active ingredient (s) is initially delivered from the dosage form.
  • amorphous sugars such as MANNOGEM TM EZ can be used to provide faster delivery during the first couple of hours to promptly produce the desired therapeutic effect, and gradually and continually release of the remaining amount to maintain the desired level of therapeutic or prophylactic effect over an extended period of time.
  • the active ingredient (s) is released at such a rate to replace the amount of the active ingredient metabolized and excreted.
  • the core can also include a wide variety of other excipients and carriers as described herein to enhance the performance of the dosage form or to promote stability or processing.
  • Materials useful in forming the semipermeable membrane include various grades of acrylics, vinyls, ethers, polyamides, polyesters, and cellulosic derivatives that are water-permeable and water-insoluble at physiologically relevant pHs or are susceptible to being rendered water-insoluble by chemical alteration, such as crosslinking.
  • Suitable polymers useful in forming the coating include plasticized, unplasticized, and reinforced cellulose acetate (CA) , cellulose diacetate, cellulose triacetate, CA propionate, cellulose nitrate, cellulose acetate butyrate (CAB) , CA ethyl carbamate, CAP, CA methyl carbamate, CA succinate, cellulose acetate trimellitate (CAT) , CA dimethylaminoacetate, CA ethyl carbonate, CA chloroacetate, CA ethyl oxalate, CA methyl sulfonate, CA butyl sulfonate, CA p-toluene sulfonate, agar acetate, amylose triacetate, beta glucan acetate, beta glucan triacetate, acetaldehyde dimethyl acetate, triacetate of locust bean gum, hydroxylated ethylene-vinylacetate, EC, PEG, PPG, P
  • Semipermeable membrane can also be a hydrophobic microporous membrane, wherein the pores are substantially filled with a gas and are not wetted by the aqueous medium but are permeable to water vapor, as disclosed in U.S. Pat. No. 5,798,119.
  • Such hydrophobic but water-vapor permeable membrane are typically composed of hydrophobic polymers such as polyalkenes, polyethylene, polypropylene, polytetrafluoroethylene, polyacrylic acid derivatives, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinylidene fluoride, polyvinyl esters and ethers, natural waxes, and synthetic waxes.
  • the delivery port (s) on the semipermeable membrane can be formed post-coating by mechanical or laser drilling. Delivery port (s) can also be formed in situ by erosion of a plug of water-soluble material or by rupture of a thinner portion of the membrane over an indentation in the core. In addition, delivery ports can be formed during coating process, as in the case of asymmetric membrane coatings of the type disclosed in U.S. Pat. Nos. 5,612,059 and 5,698,220.
  • the total amount of the active ingredient (s) released and the release rate can substantially be modulated via the thickness and porosity of the semipermeable membrane, the composition of the core, and the number, size, and position of the delivery ports.
  • the pharmaceutical composition in an osmotic controlled-release dosage form can further comprise additional conventional excipients or carriers as described herein to promote performance or processing of the formulation.
  • the osmotic controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art. See, e.g., Remington: The Science and Practice of Pharmacy, supra; Santus and Baker, J. Controlled Release, 1995, 35, 1-21; Verma et al., Drug Dev. Ind. Pharm., 2000, 26, 695-708; Verma et al., J. Controlled Release, 2002, 79, 7-27.
  • the pharmaceutical composition provided herein is formulated as an AMT controlled-release dosage form, which comprises an asymmetric osmotic membrane that coats a core comprising the active ingredient (s) and other pharmaceutically acceptable excipients or carriers.
  • AMT controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art, including direct compression, dry granulation, wet granulation, and a dip-coating method.
  • the pharmaceutical composition provided herein is formulated as an ESC controlled-release dosage form, which comprises an osmotic membrane that coats a core comprising the active ingredient (s) , a hydroxyethyl cellulose, and other pharmaceutically acceptable excipients or carriers.3. Multiparticulate Controlled Release Devices
  • the pharmaceutical composition provided herein in a modified release dosage form can be fabricated as a multiparticulate controlled release device, which comprises a multiplicity of particles, granules, or pellets, ranging from about 10 ⁇ m to about 3 mm, about 50 ⁇ m to about 2.5 mm, or from about 100 ⁇ m to about 1 mm in diameter.
  • Such multiparticulates can be made by the processes known to those skilled in the art, including wet-and dry-granulation, extrusion/spheronization, roller-compaction, melt-congealing, and by spray-coating seed cores.
  • excipients or carriers as described herein can be blended with the pharmaceutical composition to aid in processing and forming the multiparticulates.
  • the resulting particles can themselves constitute the multiparticulate device or can be coated by various film-forming materials, such as enteric polymers, water-swellable, and water-soluble polymers.
  • the multiparticulates can be further processed as a capsule or a tablet.4. Targeted Delivery
  • compositions provided herein can also be formulated to be targeted to a particular tissue, receptor, or other area of the body of the subject to be treated, including liposome-, resealed erythrocyte-, and antibody-based delivery systems. Examples include, but are not limited to, those disclosed in U.S. Pat. Nos.
  • a method of treating, preventing, or ameliorating one or more symptoms of a PAK4-mediated disorder, disease, or condition in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound provided herein, e.g., a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • a compound provided herein e.g., a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a
  • the PAK4-mediated disorder, disease, or condition is a proliferative disease.
  • a method of treating, preventing, or ameliorating one or more symptoms of a proliferative disease in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound provided herein, e.g., a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • a compound provided herein e.g., a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a diastereomer, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt,
  • the proliferative disease is cancer.
  • the cancer is refractory and/or relapsed.
  • the cancer is refractory.
  • the cancer is relapsed.
  • the cancer is metastatic.
  • the cancer is unresectable.
  • the cancer is drug-resistant. In certain embodiment, the cancer is multidrug-resistant. In certain embodiments, the cancer is resistant to a chemotherapy. In certain embodiments, the cancer is resistant to an immunotherapy. In certain embodiments, the cancer is resistant to a standard therapy for the cancer.
  • the subject is a mammal. In certain embodiments, the subject is a human.
  • the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 100 mg/kg/day, from about 0.1 to about 50 mg/kg/day, from about 0.1 to about 25 mg/kg/day, from about 0.1 to about 20 mg/kg/day, from about 0.1 to about 15 mg/kg/day, from about 0.1 to about 10 mg/kg/day, or from about 0.1 to about 5 mg/kg/day.
  • the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 100 mg/kg/day.
  • the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 50 mg/kg/day.
  • the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 25 mg/kg/day. In yet another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 20 mg/kg/day. In yet another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 15 mg/kg/day. In yet another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 10 mg/kg/day. In still another embodiment, the therapeutically effective amount of a compound provided herein is ranging from about 0.1 to about 5 mg/kg/day.
  • the administered dose can also be expressed in units other than mg/kg/day.
  • doses for parenteral administration can be expressed as mg/m 2 /day.
  • doses for parenteral administration can be expressed as mg/m 2 /day.
  • One of ordinary skill in the art would readily know how to convert doses from mg/kg/day to mg/m 2 /day to given either the height or weight of a subject or both. For example, a dose of 1 mg/m 2 /day for a 65 kg human is approximately equal to 58 mg/kg/day.
  • a compound provided herein may be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous, CIV, intracisternal injection or infusion, subcutaneous injection, or implant) , inhalation, nasal, vaginal, rectal, sublingual, or topical (e.g., transdermal or local) routes of administration.
  • parenteral e.g., intramuscular, intraperitoneal, intravenous, CIV, intracisternal injection or infusion, subcutaneous injection, or implant
  • inhalation nasal, vaginal, rectal, sublingual, or topical (e.g., transdermal or local) routes of administration.
  • a compound provided herein may be formulated in suitable dosage unit with a pharmaceutically acceptable excipient, carrier, adjuvant, or vehicle, appropriate for each route of administration.
  • a compound provided herein is administered orally. In another embodiment, a compound provided herein is administered parenterally. In yet another embodiment, a compound provided herein is administered intravenously. In yet another embodiment, a compound provided herein is administered intramuscularly. In yet another embodiment, a compound provided herein is administered subcutaneously. In still another embodiment, a compound provided herein is administered topically.
  • a compound provided herein can be delivered as a single dose such as, e.g., a single bolus injection, or oral tablets or pills; or over time such as, e.g., continuous infusion over time or divided bolus doses over time.
  • a compound provided herein can be administered repetitively, if necessary, for example, until the subject experiences stable disease or regression, or until the subject experiences disease progression or unacceptable toxicity.
  • a compound provided herein can be administered once daily (QD) or divided into multiple daily doses such as twice daily (BID) , and three times daily (TID) .
  • the administration can be continuous, i.e., every day, or intermittently.
  • the term “intermittent” or “intermittently” as used herein is intended to mean stopping and starting at either regular or irregular intervals.
  • intermittent administration of a compound provided herein is administration for one to six days per week, administration in cycles (e.g., daily administration for two to eight consecutive weeks, then a rest period with no administration for up to one week) , or administration on alternate days.
  • a compound provided herein is cyclically administered to a subject. Cycling therapy involves the administration of an active agent for a period of time, followed by a rest for a period of time, and repeating this sequential administration. Cycling therapy can reduce the development of resistance to one or more of the therapies, avoid or reduce the side effects of one of the therapies, and/or improves the efficacy of the treatment.
  • a compound provided herein can also be combined or used in combination with other therapeutic agents useful in the treatment and/or prevention of a condition, disorder, or disease described herein.
  • the term “in combination” includes the use of more than one therapy (e.g., one or more prophylactic and/or therapeutic agents) .
  • the use of the term “in combination” does not restrict the order in which therapies (e.g., prophylactic and/or therapeutic agents) are administered to a subject with a disease or disorder.
  • a first therapy e.g., a prophylactic or therapeutic agent such as a compound provided herein
  • a first therapy can be administered prior to (e.g., 5 minutes, 15 minutes, 50 minutes, 65 minutes, 1 hour, 2 hours, 6 hours, 6 hours, 12 hours, 26 hours, 68 hours, 72 hours, 96 hours, 1 week, 2 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before) , concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 50 minutes, 65 minutes, 1 hour, 2 hours, 6 hours, 12 hours, 26 hours, 68 hours, 72 hours, 96 hours, 1 week, 2 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapy (e.g., a prophylactic or therapeutic agent) to the subject.
  • a second therapy e.g., a prophylactic or therapeutic agent
  • a compound provided herein is administered orally.
  • a compound provided herein is administered intravenously.
  • the second therapy can be administered orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraocularly, via local delivery by catheter or stent, subcutaneously, intraadiposally, intraarticularly, intrathecally, or in a slow release dosage form.
  • a compound provided herein and a second therapy are administered by the same mode of administration, orally or by IV.
  • a compound provided herein is administered by one mode of administration, e.g., by IV, whereas the second agent (an anticancer agent) is administered by another mode of administration, e.g., orally.
  • a method of inhibiting the growth of a cell comprising contacting the cell with an effective amount of a compound provided herein, e.g., a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • a compound provided herein e.g., a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • the cell is a cancerous cell. In certain embodiments, the cell is a human cell. In certain embodiments, the cell is a human cancerous cell.
  • a method of inducing degradation of a PAK4 protein comprising contacting the PAK4 protein with an effective amount of a compound provided herein, e.g., a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • a compound provided herein e.g., a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • a compound provided herein can also be provided as an article of manufacture using packaging materials well known to those of skill in the art. See, e.g., U.S. Pat. Nos. 5,525,907; 5,052,558; and 5,055,252.
  • packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.
  • kits which, when used by a medical practitioner, can simplify the administration of an appropriate amount of a compound provided herein as an active ingredient to a subject.
  • the kit provided herein includes a container and a dosage form of a compound provided herein.
  • Kits provided herein can further include devices that are used to administer the active ingredients. Examples of such devices include, but are not limited to, syringes, needle-less injectors drip bags, patches, and inhalers. The kits provided herein can also include condoms for administration of the active ingredients.
  • Kits provided herein can further include pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients.
  • the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration.
  • Examples of pharmaceutically acceptable vehicles include, but are not limited to: aqueous vehicles, including, but not limited to, water for injection USP, sodium chloride injection, Ringer’s injection, dextrose injection, dextrose and sodium chloride injection, and lactated Ringer’s injection; water-miscible vehicles, including, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles, including, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
  • aqueous vehicles including, but not limited to, water for injection USP, sodium chloride injection, Ringer’s injection, dextrose injection, dextrose and sodium chloride injection, and lactated Ringer’s injection
  • water-miscible vehicles including, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene
  • g grams
  • mg milligrams
  • mL milliliters
  • ⁇ L microliters
  • mM millimolar
  • ⁇ M micromolar
  • mmol millimoles
  • min minute or minutes
  • h hour or hours
  • Boc tert-butoxycarbonyl
  • DCM diichloromethane
  • DIEA or DIPEA N, N-diisopropylethylamine
  • DMA dimethylacetamide
  • DMSO dimethylsulfoxide
  • EtOAc ethyl acetate
  • EtOH ethanol
  • HATU 1- [bis (dimethyl-amino) methylene] -1H-1, 2, 3-triazolo [4, 5-b] pyridinium 3-oxide hex
  • Step 1 Synthesis of tert-butyl 4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carboxylate (Compound 1-3) .
  • Step 2 Synthesis of 2- (2, 6-dioxopiperidin-3-yl) -4- (4- (piperazin-1-ylmethyl) piperidin-1-yl) isoindoline-1, 3-dione (Compound 1-4) .
  • reaction mixture was filtered and the filter cake was concentrated in vacuo to give the desired product 2- (2, 6-dioxopiperidin-3-yl) -4- (4- (piperazin-1-ylmethyl) piperidin-1-yl) isoindoline-1, 3-dione 1-4 (22 g, yield: 92.4%, 2HCl) as a yellow solid.
  • Step 3 Synthesis of tert-butyl (2- (4-bromophenoxy) ethyl) carbamate (Compound 1-6) .
  • Step 4 Synthesis of methyl 4'- (2- ( (tert-butoxycarbonyl) amino) ethoxy) - [1, 1'-biphenyl] -4-carboxylate (Compound 1-7) .
  • Step 5 Synthesis of methyl 4'- (2-aminoethoxy) - [1, 1'-biphenyl] -4-carboxylate (Compound 1-8) .
  • Step 6 Synthesis of methyl (E) -4'- (2- (3- (pyridin-2-yl) acrylamido) ethoxy) - [1, 1'-biphenyl] -4-carboxylate (Compound 1-9) .
  • Step 7 Synthesis of (E) -4'- (2- (3- (pyridin-2-yl) acrylamido) ethoxy) - [1, 1'-biphenyl] -4-carboxylic acid (Compound 1-10) .
  • Step 8 Synthesis of (E) -N- (2- ( (4'- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) - [1, 1'-biphenyl] -4-yl) oxy) ethyl) -3- (pyridin-2-yl) acrylamide (Compound 1) .
  • Step 2 Synthesis of methyl 4'- (2- ( (tert-butoxycarbonyl) amino) ethoxy) -3'-fluoro- [1, 1'-biphenyl] -4-carboxylate (Compound 2-3)
  • Step 3 Synthesis of methyl 4'- (2-aminoethoxy) -3'-fluoro- [1, 1'-biphenyl] -4-carboxylate (Compound 2-4)
  • Step 4 Synthesis of methyl (E) -3'-fluoro-4'- (2- (3- (pyridin-2-yl) acrylamido) ethoxy) - [1, 1'-biphenyl] -4-carboxylate (Compound 2-6)
  • Step 5 Synthesis of (E) -3'-fluoro-4'- (2- (3- (pyridin-2-yl) acrylamido) ethoxy) - [1, 1'-biphenyl] -4-carboxylic acid (Compound 2-7)
  • Step 6 Synthesis of (E) -N- (2- ( (4'- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) -3-fluoro- [1, 1'-biphenyl] -4-yl) oxy) ethyl) -3- (pyridin-2-yl) acrylamide (Compound 2)
  • Step 1 Synthesis of tert-butyl (2- (4-bromo-2-chlorophenoxy) ethyl) carbamate (Compound 3-2) .
  • Step 2 Synthesis of methyl 4'- (2- ( (tert-butoxycarbonyl) amino) ethoxy) -3'-chloro- [1, 1'-biphenyl] -4-carboxylate (Compound 3-3) .
  • Step 3 Synthesis of methyl 4'- (2-aminoethoxy) -3'-chloro- [1, 1'-biphenyl] -4-carboxylate (Compound3-4) .
  • Step 4 Synthesis of methyl (E) -3'-chloro-4'- (2- (3- (pyridin-2-yl) acrylamido) ethoxy) - [1, 1'-biphenyl] -4-carboxylate (Compound 3-5) .
  • Step 5 Synthesis of (E) -3'-chloro-4'- (2- (3- (pyridin-2-yl) acrylamido) ethoxy) - [1, 1'-biphenyl] -4-carboxylic acid (Compound 3-6) .
  • Step 6 Synthesis of (E) -N- (2- ( (3-chloro-4'- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) - [1, 1'-biphenyl] -4-yl) oxy) ethyl) -3- (pyridin-2-yl) acrylamide (Compound 3) .
  • Step 1 Synthesis of tert-butyl (2- (4-bromo-2-cyanophenoxy) ethyl) carbamate (Compound 4-2)
  • Step 2 Synthesis of methyl 4'- (2- ( (tert-butoxycarbonyl) amino) ethoxy) -3'-cyano- [1, 1'-biphenyl] -4-carboxylate (Compound 4-3)
  • Step 3 Synthesis of methyl 4'- (2-aminoethoxy) -3'-cyano- [1, 1'-biphenyl] -4-carboxylate (Compound 4-4)
  • Step 4 Synthesis of methyl (E) -3'-cyano-4'- (2- (3- (pyridin-2-yl) acrylamido) ethoxy) - [1, 1'-biphenyl] -4-carboxylate (Compound 4-5)
  • Step 5 Synthesis of (E) -3'-cyano-4'- (2- (3- (pyridin-2-yl) acrylamido) ethoxy) - [1, 1'-biphenyl] -4-carboxylic acid (Compound 4-6)
  • Step 6 Synthesis of (E) -N- (2- ( (3-cyano-4'- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) - [1, 1'-biphenyl] -4-yl) oxy) ethyl) -3- (pyridin-2-yl) acrylamide (Compound 4)
  • Step 1 Synthesis of tert-butyl (2- ( (5-bromopyridin-2-yl) oxy) ethyl) carbamate (Compound 5-2)
  • Step 2 Synthesis of methyl 4- (6- (2- ( (tert-butoxycarbonyl) amino) ethoxy) pyridin-3-yl) benzoate (Compound 5-3)
  • Step 4 Synthesis of methyl (E) -4- (6- (2- (3- (pyridin-2-yl) acrylamido) ethoxy) pyridin-3-yl) benzoate (Compound 5-5)
  • Step 5 Synthesis of (E) -4- (6- (2- (3- (pyridin-2-yl) acrylamido) ethoxy) pyridin-3-yl) benzoic acid (Compound 5-6)
  • Step 6 Synthesis of (E) -N- (2- ( (5- (4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) phenyl) pyridin-2-yl) oxy) ethyl) -3- (pyridin-2-yl) acrylamide (Compound 5)
  • Step 1 Synthesis of tert-butyl (2- (5-bromo-2-oxopyridin-1 (2H) -yl) ethyl) carbamate (Compound 6-2)
  • Step 2 Synthesis of methyl 4- (1- (2- ( (tert-butoxycarbonyl) amino) ethyl) -6-oxo-1, 6-dihydropyridin-3-yl) benzoate (Compound 6-3)
  • the reaction mixture was diluted with H 2 O (100 mL) and extracted with DCM (3 ⁇ 200 mL) . The combined organic layers were dried over Na 2 SO 4 , filtered and the filtrate was concentrated to dryness to give the crude product.
  • the crude product was triturated with ethyl acetate (10 mL) to form a slurry, which was then filtered to obtain methyl 4- (1- (2- ( (tert-butoxycarbonyl) amino) ethyl) -6-oxo-1, 6-dihydropyridin-3-yl) benzoate 6-3 (3.3 g, yield: 66%) as a brown solid.
  • Step 3 Synthesis of methyl 4- (1- (2-aminoethyl) -6-oxo-1, 6-dihydropyridin-3-yl) benzoate hydrochloride (Compound 6-4)
  • Step 4 Synthesis of methyl (E) -4- (6-oxo-1- (2- (3- (pyridin-2-yl) acrylamido) ethyl) -1, 6-dihydropyridin-3-yl) benzoate (Compound 6-5)
  • Step 5 Synthesis of (E) -4- (6-oxo-1- (2- (3- (pyridin-2-yl) acrylamido) ethyl) -1, 6-dihydropyridin-3-yl) benzoic acid (Compound 6-6)
  • Step 6 Synthesis of (E) -N- (2- (5- (4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) phenyl) -2-oxopyridin-1 (2H) -yl) ethyl) -3- (pyridin-2-yl) acrylamide (Compound 6)
  • Step 1 Synthesis of tert-butyl (2- (4-bromo-2-oxopyridin-1 (2H) -yl) ethyl) carbamate (Compound 7-2)
  • Step 2 Synthesis of methyl 4- (1- (2- ( (tert-butoxycarbonyl) amino) ethyl) -2-oxo-1, 2-dihydropyridin-4-yl) benzoate (Compound 7-3)
  • Step 3 Synthesis of methyl 4- (1- (2-aminoethyl) -2-oxo-1, 2-dihydropyridin-4-yl) benzoate hydrochloride (Compound 7-4)
  • Step 4 Synthesis of methyl (E) -4- (2-oxo-1- (2- (3- (pyridin-2-yl) acrylamido) ethyl) -1, 2-dihydropyridin-4-yl) benzoate (Compound 7-5)
  • Step 5 Synthesis of (E) -4- (2-oxo-1- (2- (3- (pyridin-2-yl) acrylamido) ethyl) -1, 2-dihydropyridin-4-yl) benzoic acid (Compound 7-6)
  • Step 6 Synthesis of (E) -N- (2- (4- (4- (4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) phenyl) -2-oxopyridin-1 (2H) -yl) ethyl) -3- (pyridin-2-yl) acrylamide (Compound 7)
  • Step 1 Synthesis of tert-butyl (2- ( (4-bromopyridin-2-yl) oxy) ethyl) carbamate (Compound 8-2)
  • Step 2 Synthesis of methyl 4- (2- (2- ( (tert-butoxycarbonyl) amino) ethoxy) pyridin-4-yl) benzoate (Compound 8-3)
  • Step 4 Synthesis of methyl (E) -4- (2- (2- (3- (pyridin-2-yl) acrylamido) ethoxy) pyridin-4-yl) benzoate (Compound 8-5)
  • Step 5 Synthesis of (E) -4- (2- (2- (3- (pyridin-2-yl) acrylamido) ethoxy) pyridin-4-yl) benzoic acid (Compound 8-6)
  • Step 6 Synthesis of (E) -N- (2- ( (4- (4- (4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) phenyl) pyridin-2-yl) oxy) ethyl) -3- (pyridin-2-yl) acrylamide (Compound 8)
  • Step 7 Synthesis of methyl 4- (2- (aminomethyl) -7-chlorobenzofuran-5-yl) benzoate (Compound 9-8)
  • Step 8 Synthesis of methyl (E) -4- (7-chloro-2- ( (3- (pyridin-2-yl) acrylamido) methyl) benzofuran-5-yl) benzoate (Compound 9-9)
  • Step 9 Synthesis of (E) -4- (7-chloro-2- ( (3- (pyridin-2-yl) acrylamido) methyl) benzofuran-5-yl) benzoic acid (Compound 9-10)
  • Step 10 Synthesis of (E) -N- ( (7-chloro-5- (4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) phenyl) benzofuran-2-yl) methyl) -3- (pyridin-2-yl) acrylamide (Compound 9)
  • Step 2 Synthesis of methyl 4'- (2- ( (tert-butoxycarbonyl) amino) ethoxy) -3'-chloro- [1, 1'-biphenyl] -4-carboxylate (Compound 10-3)
  • Step 3 Synthesis of methyl 4'- (2-aminoethoxy) -3'-chloro- [1, 1'-biphenyl] -4-carboxylate (Compound 10-4)
  • Step 4 Synthesis of methyl (E) -4'- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3'-chloro- [1, 1'-biphenyl] -4-carboxylate (Compound 10-5)
  • the reaction mixture was poured into ice-water (50 mL) , the precipitate was collected by filtration through a pad of Celite. The filter cake was washed with water (20 mL) , then dissolved into THF (30 mL) , and filtered.
  • Step 5 Synthesis of (E) -4'- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3'-chloro- [1, 1'-biphenyl] -4-carboxylic acid (Compound 10-6)
  • Step 6 Synthesis of tert-butyl (E) -4- ( (4- (4'- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3'-chloro- [1, 1'-biphenyl] -4-carbonyl) piperazin-1-yl) methyl) piperidine-1-carboxylate (Compound 10-7)
  • Step 7 Synthesis of (E) -3- (6-aminopyridin-3-yl) -N- (2- ( (3-chloro-4'- (4- (piperidin-4-ylmethyl) piperazine-1-carbonyl) - [1, 1'-biphenyl] -4-yl) oxy) ethyl) acrylamide (Compound 10-8)
  • Step 8 Synthesis of (E) -3- (6-aminopyridin-3-yl) -N- (2- ( (3-chloro-4'- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) - [1, 1'-biphenyl] -4-yl) oxy) ethyl) acrylamide (Compound 10)
  • Step 1 Synthesis of (E) -3- (6-aminopyridin-3-yl) -N- (2- ( (3-chloro-4'- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -6-fluoro-1, 3-dioxoisoindolin-5-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) - [1, 1'-biphenyl] -4-yl) oxy) ethyl) acrylamide (Compound 11)
  • Step 1 Synthesis of methyl 4'- (2- ( (tert-butoxycarbonyl) amino) ethoxy) -3'-chloro-2, 3, 4, 5-tetrahydro- [1, 1'-biphenyl] -4-carboxylate (Compound 12-1)
  • Step 2 Synthesis of methyl 4'- (2-aminoethoxy) -3'-chloro-2, 3, 4, 5-tetrahydro- [1, 1'-biphenyl] -4-carboxylate (Compound 12-2)
  • Step 3 Synthesis of methyl (E) -4'- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3'-chloro-2, 3, 4, 5-tetrahydro- [1, 1'-biphenyl] -4-carboxylate (Compound 12-3)
  • Step 4 Synthesis of (E) -4'- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3'-chloro-2, 3, 4, 5-tetrahydro- [1, 1'-biphenyl] -4-carboxylic acid (Compound 12-4)
  • Step 5 Synthesis of tert-butyl (E) -4- ( (4- (4'- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3'-chloro-2, 3, 4, 5-tetrahydro- [1, 1'-biphenyl] -4-carbonyl) piperazin-1-yl) methyl) piperidine-1-carboxylate (Compound 12-5)
  • Step 6 Synthesis of (E) -3- (6-aminopyridin-3-yl) -N- (2- ( (3-chloro-4'- (4- (piperidin-4-ylmethyl) piperazine-1-carbonyl) -2', 3', 4', 5'-tetrahydro- [1, 1'-biphenyl] -4-yl) oxy) ethyl) acrylamide (Compound 12-6)
  • Step 7 Synthesis of (E) -3- (6-aminopyridin-3-yl) -N- (2- ( (3-chloro-4'- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) -2', 3', 4', 5'-tetrahydro- [1, 1'-biphenyl] -4-yl) oxy) ethyl) acrylamide (Compound 12)
  • Step 1 Synthesis of methyl 4- (4- (2- ( (tert-butoxycarbonyl) amino) ethoxy) -3-chlorophenyl) cyclohexane-1-carboxylate (Compound 13-1)
  • Step 2 Synthesis of methyl 4- (4- (2-aminoethoxy) -3-chlorophenyl) cyclohexane-1-carboxylate (Compound 13-2)
  • Step 3 Synthesis of methyl (E) -4- (4- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3-chlorophenyl) cyclohexane-1-carboxylate (Compound 13-3)
  • Step 4 Synthesis of (E) -4- (4- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3-chlorophenyl) cyclohexane-1-carboxylic acid (Compound 13-4)
  • Step 5 Synthesis of tert-butyl (E) -4- ( (4- (4- (4- (4- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3-chlorophenyl) cyclohexane-1-carbonyl) piperazin-1-yl) methyl) piperidine-1-carboxylate (Compound 13-5)
  • Step 6 Synthesis of (E) -3- (6-aminopyridin-3-yl) -N- (2- (2-chloro-4- (4- (4- (piperidin-4-ylmethyl) piperazine-1-carbonyl) cyclohexyl) phenoxy) ethyl) acrylamide (Compound 13-6)
  • Step 6 Synthesis of (E) -3- (6-aminopyridin-3-yl) -N- (2- (2-chloro-4- (4- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) cyclohexyl) phenoxy) ethyl) acrylamide (Compound 13)
  • Step 1 Synthesis of tert-butyl (2- (4-bromo-2- (trifluoromethyl) phenoxy) ethyl) carbamate (Compound 14-2)
  • Step 2 Synthesis of ethyl 4'- (2- ( (tert-butoxycarbonyl) amino) ethoxy) -3'- (trifluoromethyl) -2, 3, 4, 5-tetrahydro- [1, 1'-biphenyl] -4-carboxylate (Compound 14-3)
  • Step 3 Synthesis of ethyl 4'- (2-aminoethoxy) -3'- (trifluoromethyl) -2, 3, 4, 5-tetrahydro- [1, 1'-biphenyl] -4-carboxylate (Compound 14-4)
  • Step 4 Synthesis of ethyl (E) -4'- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3'- (trifluoromethyl) -2, 3, 4, 5-tetrahydro- [1, 1'-biphenyl] -4-carboxylate (Compound 14-5)
  • the mixture was stirred at 25 °C for 2 hrs. TLC showed starting materials was consumed completely and new spot was formed.
  • the reaction mixture was poured into ice-water (25 mL) and extracted with DCM (10 mL x3) . The combined organic layer was washed with brine (10 mL x3) , dried over Na 2 SO 4 and filtered.
  • Step 5 Synthesis of (E) -4'- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3'- (trifluoromethyl) -2, 3, 4, 5-tetrahydro- [1, 1'-biphenyl] -4-carboxylic acid (Compound 14-6)
  • Step 6 Synthesis of tert-butyl (E) -4- ( (4- (4'- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3'- (trifluoromethyl) -2, 3, 4, 5-tetrahydro- [1, 1'-biphenyl] -4-carbonyl) piperazin-1-yl) methyl) piperidine-1-carboxylate (Compound 14-7)
  • reaction mixture was stirred at 25 °C for 2 hrs. TLC showed starting materials was consumed completely and new spot was formed.
  • the reaction mixture was poured into ice-water (25mL) and extracted with DCM (10 mL x3) . The combined organic layer was washed with brine (10 mL x3) , dried over Na 2 SO 4 and filtered.
  • Step 6 Synthesis of (E) -3- (6-aminopyridin-3-yl) -N- (2- ( (4'- (4- (piperidin-4-ylmethyl) piperazine-1-carbonyl) -3- (trifluoromethyl) -2', 3', 4', 5'-tetrahydro- [1, 1'-biphenyl] -4-yl) oxy) ethyl) acrylamide (Compound 14-8)
  • Step 7 Synthesis of (E) -3- (6-aminopyridin-3-yl) -N- (2- ( (4'- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) -3- (trifluoromethyl) -2', 3', 4', 5'-tetrahydro- [1, 1'-biphenyl] -4-yl) oxy) ethyl) acrylamide (Compound 14)
  • the mixture was stirred at 90 °C for 3 hrs. TLC showed starting materials was consumed completely and new spot was formed.
  • the reaction mixture was poured into ice-water (70 mL) and extracted with EtOAc (70 mLx3) . The combined organic layer was washed with brine (70 mL x3) , dried over Na 2 SO 4 and filtered.
  • Step 1 Synthesis of methyl 4'- (2- ( (tert-butoxycarbonyl) amino) ethoxy) -3'- (trifluoromethyl) - [1, 1'-biphenyl] -4-carboxylate (Compound 15-1)
  • Step 2 Synthesis of methyl 4'- (2-aminoethoxy) -3'- (trifluoromethyl) - [1, 1'-biphenyl] -4-carboxylate (Compound 15-2)
  • Step 3 Synthesis of methyl (E) -4'- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3'-chloro- [1, 1'-biphenyl] -4-carboxylate (Compound 15-3)
  • Step 4 Synthesis of (E) -4'- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3'- (trifluoromethyl) - [1, 1'-biphenyl] -4-carboxylic acid (Compound 15-4)
  • Step 5 Synthesis of tert-butyl (E) -4- ( (4- (4'- (2- (3- (6-aminopyridin-3-yl) acrylamido) ethoxy) -3'- (trifluoromethyl) - [1, 1'-biphenyl] -4-carbonyl) piperazin-1-yl) methyl) piperidine-1-carboxylate (Compound 15-5)
  • the mixture was stirred at 25 °C for 2 hrs. TLC showed starting materials was consumed completely and new spot was formed.
  • the reaction mixture was poured into ice-water (25 mL) and extracted with DCM (10 mL x3) . The combined organic layer was washed with brine (10 mL x3) , dried over Na 2 SO 4 and filtered.
  • Step 6 Synthesis of (E) -3- (6-aminopyridin-3-yl) -N- (2- ( (4'- (4- (piperidin-4-ylmethyl) piperazine-1-carbonyl) -3- (trifluoromethyl) - [1, 1'-biphenyl] -4-yl) oxy) ethyl) acrylamide (Compound 15-6)
  • Step 7 Synthesis of (E) -3- (6-aminopyridin-3-yl) -N- (2- ( (4'- (4- ( (1- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperidin-4-yl) methyl) piperazine-1-carbonyl) -3- (trifluoromethyl) - [1, 1'-biphenyl] -4-yl) oxy) ethyl) acrylamide (Compound 15)
  • the mixture was stirred at 90 °C for 3 hrs. TLC showed starting materials was consumed completely and new spot was formed.
  • the reaction mixture was poured into ice-water (70 mL) and extracted with EtOAc (70 mL x3) . The combined organic layer was washed with brine (70 mL x3) , dried over Na 2 SO 4 and filtered.
  • Step 1 Synthesis of tert-butyl 4- ( (4- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperazin-1-yl) methyl) piperidine-1-carboxylate (Compound 16-2)
  • Step 2 Synthesis 2- (2, 6-dioxopiperidin-3-yl) -4- (4- (piperidin-4-ylmethyl) piperazin-1-yl) isoindoline-1, 3-dione (Compound 16-3)
  • Step 3 Synthesis (E) -N- ( (7-chloro-5- (4- (4- ( (4- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperazin-1-yl) methyl) piperidine-1-carbonyl) phenyl) benzofuran-2-yl) methyl) -3- (pyridin-2-yl) acrylamide (Compound 16)
  • Step 3 Synthesis of tert-butyl 4- (piperazin-1-ylmethyl) -4- ( (trimethylsilyl) oxy) piperidine-1-carboxylate (Compound 17-4)
  • Step 4 Synthesis of tert-butyl 4- ( (4- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperazin-1-yl) methyl) -4- ( (trimethylsilyl) oxy) piperidine-1-carboxylate (Compound 17-5)
  • the reaction was purified by reversed-phase flash chromatography with the conditions (column, C18 silica gel; mobile phase, ACN in H2O (0.1%FA) . 10%to 100%gradient in 20 min; detector. UV 254/220 nm) to afford tert-butyl 4- ( (4- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperazin-1-yl) methyl) -4- ( (trimethylsilyl) oxy) piperidine-1-carboxylate (280 mg, yield: 31.27%) as a yellow solid.
  • Step 5 Synthesis of 2- (2, 6-dioxopiperidin-3-yl) -4- (4- ( (4-hydroxypiperidin-4-yl) methyl) piperazin-1-yl) isoindoline-1, 3-dione (Compound 17-6)
  • Step 6 Synthesis of (E) -N- ( (7-chloro-5- (4- (4- ( (4- (2- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-4-yl) piperazin-1-yl) methyl) -4-hydroxypiperidine-1-carbonyl) phenyl) benzofuran-2-yl) methyl) -3- (pyridin-2-yl) acrylamide (Compound 17)
  • the mixture was stirred for 2 hrs at 25 °C under N 2 atmosphere.
  • the reaction progress was monitored by LCMS.
  • the reaction was purified by reversed-phase flash chromatography with the conditions (column, C18 silica gel; mobile phase, ACN in H2O (0.1%FA) . 10%to 100%gradient in 20 min; detector.
  • cDNA Complementary DNA for human PAK4 was amplified from reverse-transcribed cDNA of SUM159 cells.
  • the PAK4 cDNA was inserted into lentiviral expression vector with C-terminal fusion of firefly luciferase for stable expression in SUM159 cells.
  • the desired gene-containing lentiviral plasmids were co-transfected into HEK293T cells with psPAX2 (Addgene #12260) and pMD2.
  • G Additional gene-containing lentiviral plasmids at a mass ratio of 5: 3: 2.
  • SUM159 cells stably expressing PAK4-luciferase were plated in 96-well flat clear-bottom white polystyrene TC-treated microplates at a density of 1 ⁇ 10 4 cells per well and incubated for 24 hours. The next day, 3-fold serial dilutions of compounds were prepared in DMSO in a manner to normalize the DMSO concentration among all cell culture wells. These cells were then treated with compound for 6 hours. After incubation, luciferase activity was measured using the Bright-Glo TM Luciferase Assay System (Promega) . Curve fitting and interpolation from the standard curve were performed with GraphPad Prism.PAK4 Protein Degradation Assay 2
  • SUM159 cells (3 x 10 5 cells/well) were seeded in a 6-well plate. The cells were incubated with a compound at predetermined concentrations or a vehicle (0.1%DMSO) as a control for 6 h. The cells were then lysed in a lysis buffer (20 mM Tris (pH 7.5) , 150 mM NaCl, 1%Triton X-100, sodium pyrophosphate, ⁇ -glycerophosphate, EDTA, Na3VO4, and leupeptin) . The total protein concentration of each collected lysate was determined using a BCA Protein Assay kit.
  • Western blot is performed according to the standard protocols. SDS–PAGE was performed with each collected lysate (10 ⁇ g of proteins loaded) . After electrophoretically separated on 4-20%SUREPAGE TM , the protein samples were transferred to nitrocellulose membranes. The nitrocellulose membranes were blocked in TBST (tris-buffered saline with 0.1%TWEEN-20 detergent) containing 5%skim milk for 1 h. After washed three times in TBST, the nitrocellulose membranes were incubated with primary antibodies overnight at 4 °C in a 1: 2,000 dilution. The primary antibodies used were PAK4 (CST Cat. 62690S) and ⁇ -Actin (CST Cat. 3700S) .
  • nitrocellulose membranes were incubated with respective secondary HRP-conjugated antibodies diluted in TBST for 1 h at room temperature.
  • the blots were visualized with a BIO-RAD CHEMIDOC Imaging System.
  • S represents a DC50 value of no greater than 50 nM (S ⁇ 50 nM) ;
  • A represents a DC50 value of greater than 50 nM but no greater than 100 nM (50 nM ⁇ A ⁇ 100nM) ;
  • B represents a DC50 value of greater than 100 nM but no greater than 500 nM (100 nM ⁇ B ⁇ 500nM) ;
  • C represents a DC50 value of greater than 500 nM (C > 500 nM) ;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des agents de dégradation de protéine PAK4, par exemple, un composé de formule (I), des compositions pharmaceutiques de celui-ci, et leur utilisation dans le traitement, la prévention ou l'atténuation d'un ou de plusieurs symptômes d'un trouble, d'une maladie ou d'un état médié par PAK4.
PCT/CN2025/098860 2024-06-04 2025-06-03 Agents de dégradation bifonctionnels de pak4, compositions pharmaceutiques et applications thérapeutiques Pending WO2025252084A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2024097169 2024-06-04
CNPCT/CN2024/097169 2024-06-04

Publications (1)

Publication Number Publication Date
WO2025252084A1 true WO2025252084A1 (fr) 2025-12-11

Family

ID=97960079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2025/098860 Pending WO2025252084A1 (fr) 2024-06-04 2025-06-03 Agents de dégradation bifonctionnels de pak4, compositions pharmaceutiques et applications thérapeutiques

Country Status (1)

Country Link
WO (1) WO2025252084A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105492437A (zh) * 2013-07-03 2016-04-13 卡尔约药物治疗公司 取代的苯并呋喃基和苯并噁唑基化合物及其用途
CN113072551A (zh) * 2020-01-03 2021-07-06 上海翰森生物医药科技有限公司 含氮联苯类衍生物抑制剂、其制备方法和应用
WO2022088551A1 (fr) * 2020-10-26 2022-05-05 上海领泰生物医药科技有限公司 Dérivé d'indazole, son procédé de préparation et son utilisation
WO2024120442A1 (fr) * 2022-12-07 2024-06-13 Convergen (Suzhou) Pharmaceutical Co., Ltd. Agents de dégradation de protéine pak4, compositions pharmaceutiques et applications thérapeutiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105492437A (zh) * 2013-07-03 2016-04-13 卡尔约药物治疗公司 取代的苯并呋喃基和苯并噁唑基化合物及其用途
CN113072551A (zh) * 2020-01-03 2021-07-06 上海翰森生物医药科技有限公司 含氮联苯类衍生物抑制剂、其制备方法和应用
WO2022088551A1 (fr) * 2020-10-26 2022-05-05 上海领泰生物医药科技有限公司 Dérivé d'indazole, son procédé de préparation et son utilisation
WO2024120442A1 (fr) * 2022-12-07 2024-06-13 Convergen (Suzhou) Pharmaceutical Co., Ltd. Agents de dégradation de protéine pak4, compositions pharmaceutiques et applications thérapeutiques

Similar Documents

Publication Publication Date Title
US11787788B2 (en) Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof
EP4355741B1 (fr) Agents de dégradation de protéine sos1, compositions pharmaceutiques de ceux-ci, et leurs applications thérapeutiques
US12138265B2 (en) Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
US20240190883A1 (en) Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2023023531A1 (fr) Agents de dégradation du récepteur des œstrogènes, compositions pharmaceutiques et applications thérapeutiques
WO2024012557A1 (fr) Agents de dégradation de protéines anti-apoptotiques de la famille bcl-2, compositions pharmaceutiques et applications thérapeutiques
WO2022212611A1 (fr) Agents de dégradation de protéine kras, compositions pharmaceutiques de ceux-ci, et leurs applications thérapeutiques
US20250186434A1 (en) Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2023185920A1 (fr) Agents de dégradation de fak, compositions pharmaceutiques et applications thérapeutiques
WO2022242582A1 (fr) Composés indènes, compositions pharmaceutiques à base de ceux-ci et leurs applications thérapeutiques
WO2024017178A1 (fr) Composes d'hydantoïne substitues, compositions pharmaceutiques et applications thérapeutiques
US20240197888A1 (en) Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2024120442A1 (fr) Agents de dégradation de protéine pak4, compositions pharmaceutiques et applications thérapeutiques
US12419962B2 (en) Quinazolines, pharmaceutical compositions, and therapeutic applications
WO2024156288A1 (fr) Inhibiteurs de dnmt1, compositions pharmaceutiques et applications thérapeutiques
WO2025252084A1 (fr) Agents de dégradation bifonctionnels de pak4, compositions pharmaceutiques et applications thérapeutiques
US12570687B2 (en) Triterpenoid compounds, pharmaceutical compositions thereof, and their use for treating a nuclear receptor subfamily 4 group a member 1-mediated disease
US20250289813A1 (en) Cdk inhibitors, pharmaceutical compositions, and therapeutic applications
WO2024104422A1 (fr) Composés contenant du phosphore pour le traitement d'une maladie inflammatoire de l'intestin
WO2024120466A1 (fr) Monosaccharides, compositions pharmaceutiques et applications diagnostiques et thérapeutiques
EP4630434A1 (fr) Monosaccharides de phosphoramidate, compositions pharmaceutiques et applications diagnostiques et thérapeutiques
WO2023023474A1 (fr) Modulateurs du tr-bêta, compositions pharmaceutiques et applications thérapeutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25819196

Country of ref document: EP

Kind code of ref document: A1